<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="34c64c32-89bd-e0a0-e063-6394a90a8ddf"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use PEMETREXED FOR INJECTION  safely and effectively. See full prescribing information for PEMETREXED FOR INJECTION.
 <br/>
PEMETREXED for injection, for Intravenous use
 <br/>
Initial U.S. Approval: 2004
</title>
   <effectiveTime value="20250510"/>
   <setId root="39219e4b-80a6-4d4f-96a3-1202e542d050"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="079947873"/>
            <name>Somerset Therapeutics LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="650213072"/>
                        <name>Reliance Life Sciences Private Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-834" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-835" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="label" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-834" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="label" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-835" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-834" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-835" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-834" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-835" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="api manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-834" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="api manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-835" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="34c6680b-d061-fad4-e063-6394a90a6cdb"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250510"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70069-834" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>
                  Pemetrexed</name>
                        <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Pemetrexed disodium</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="106"/>
                              <denominator unit="mL" value="4"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="100"/>
                              <denominator unit="mL" value="4"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="9T47E4OM16" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PEMETREXED DISODIUM HEPTAHYDRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="04Q9AIZ7NO" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PEMETREXED</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="4" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="70069-834-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250415"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA211899" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250415"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70069-835" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>
                  Pemetrexed</name>
                        <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Pemetrexed disodium</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="500"/>
                              <denominator unit="mL" value="20"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="500"/>
                              <denominator unit="mL" value="20"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="9T47E4OM16" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PEMETREXED DISODIUM HEPTAHYDRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="04Q9AIZ7NO" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PEMETREXED</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="20" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="70069-835-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250415"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA211899" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250415"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s1">
               <id root="34c64c32-89be-e0a0-e063-6394a90a8ddf"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20250508"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Pemetrexed for injection is a folate analog metabolic inhibitor indicated:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. (
  
     <linkHtml href="#undefined">1.1</linkHtml>)
 
    </item>
                           <item>in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous (NSCLC). (
  
     <linkHtml href="#undefined">1.1</linkHtml>)
 
    </item>
                           <item>as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. (
  
     <linkHtml href="#undefined">1.1</linkHtml>)
 
    </item>
                           <item>as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy. (
  
     <linkHtml href="#undefined">1.1</linkHtml>)  
 
    </item>
                        </list>
                        <paragraph>
                           <content styleCode="underline"/>
                           <content styleCode="underline">Limitations of Use:</content>Pemetrexed for injection is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer. (
 
    <linkHtml href="#undefined">1.1</linkHtml>) 
    <br/>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. (
  
     <linkHtml href="#undefined">1.2</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s2">
                     <id root="34c64c32-89bf-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Non-Squamous Non-Small Cell Lung Cancer (NSCLC)</title>
                     <text>
                        <paragraph>Pemetrexed for injection is indicated:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.</item>
                           <item>in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous, NSCLC.</item>
                           <item>as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.</item>
                           <item>as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy.</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use:</content>Pemetrexed for injection is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer 
 
  <content styleCode="italics">[see Clinical Studies</content>
                           <linkHtml href="#s78">14.1</linkHtml>
                           <content styleCode="italics">].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
               <component>
                  <section ID="s4">
                     <id root="34c64c32-89c0-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Mesothelioma</title>
                     <text>
                        <paragraph>Pemetrexed for injection is indicated, in combination with cisplatin, for the initial treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.</paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s5">
               <id root="34c64c32-89c1-e0a0-e063-6394a90a8ddf"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250508"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>The recommended dose of pemetrexed for injection administered with pembrolizumab and platinum chemotherapy in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m
  
     <sup>2</sup>as an intravenous infusion over 10 minutes, administered after pembrolizumab and prior to platinum chemotherapy, on Day 1 of each 21-day cycle. (
  
     <linkHtml href="#undefined">2.1</linkHtml>)
 
    </item>
                           <item>The recommended dose of pemetrexed for injection, administered as a single agent or with cisplatin, in patients with creatinine clearance of 45 mL/minute or greater is 500 mg/m
  
     <sup>2</sup>as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle. (
  
     <linkHtml href="#undefined">2.1</linkHtml>,
  
     <linkHtml href="#undefined">2.2</linkHtml>)
 
    </item>
                           <item>Initiate folic acid 400 mcg to 1000 mcg orally, once daily, beginning 7 days prior to the first dose of pemetrexed for injection and continue until 21 days after the last dose of pemetrexed for injection. (
  
     <linkHtml href="#undefined">2.4</linkHtml>)
 
    </item>
                           <item>Administer vitamin B
  
     <sub>12</sub>, 1 mg intramuscularly, 1 week prior to the first dose of pemetrexed for injection and every 3 cycles. (
  
     <linkHtml href="#undefined">2.4</linkHtml>)
 
    </item>
                           <item>Administer dexamethasone 4 mg orally, twice daily the day before, the day of, and the day after pemetrexed for injection administration. (
  
     <linkHtml href="#undefined">2.4</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s6">
                     <id root="34c64c32-89c2-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Dosage for Non-Squamous NSCLC</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>The recommended dose of pemetrexed for injection when administered with pembrolizumab and platinum chemotherapy for the initial treatment of metastatic non-squamous NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m
  
   <sup>2</sup>as an intravenous infusion over 10 minutes administered after pembrolizumab and prior to carboplatin or cisplatin on Day 1 of each 21-day cycle for 4 cycles. Following completion of platinum-based therapy, treatment with pemetrexed for injection with or without pembrolizumab is administered until disease progression or unacceptable toxicity. Please refer to the full prescribing information for pembrolizumab and for carboplatin or cisplatin.
 
  </item>
                           <item>The recommended dose of pemetrexed for injection when administered with cisplatin for initial treatment of locally advanced or metastatic non-squamous NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m
  
   <sup>2</sup>as an intravenous infusion over 10 minutes administered prior to cisplatin on Day 1 of each 21-day cycle for up to six cycles in the absence of disease progression or unacceptable toxicity.
 
  </item>
                           <item>The recommended dose of pemetrexed for injection for maintenance treatment of non-squamous NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m
  
   <sup>2</sup>as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity after four cycles of platinum-based first-line chemotherapy.
 
  </item>
                           <item>The recommended dose of pemetrexed for injection for treatment of recurrent non-squamous NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m
  
   <sup>2</sup>as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
 
  </item>
                        </list>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
               <component>
                  <section ID="s7">
                     <id root="34c64c32-89c3-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Recommended Dosage for Mesothelioma</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>The recommended dose of pemetrexed for injection when administered with cisplatin in patients  with  a  creatinine  clearance  (calculated  by  Cockcroft-Gault  equation)  of  45  mL/min  or greater is 500 mg/m
  
   <sup>2</sup>as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
 
  </item>
                        </list>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
               <component>
                  <section ID="s8">
                     <id root="34c64c32-89c4-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Renal Impairment</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Pemetrexed  for  injection  dosing  recommendations  are  provided  for  patients  with  a  creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater [
  
   <content styleCode="italics">see Dosage and Administration (</content>
                              <content styleCode="italics">
                                 <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark0">2.1</linkHtml>
                              </content>
                              <content styleCode="italics">, 2.2)</content>]. There is no recommended dose for patients whose creatinine clearance is less than 45 mL/min [
  
   <content styleCode="italics">see Use in Specific Populations (</content>
                              <content styleCode="italics">
                                 <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark12">8.6</linkHtml>
                              </content>
                              <content styleCode="italics">)</content>].
 
  </item>
                        </list>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
               <component>
                  <section ID="s9">
                     <id root="34c64c32-89c5-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Premedication and Concomitant Medications to Mitigate Toxicity</title>
                     <effectiveTime value="20250508"/>
                     <component>
                        <section ID="s10">
                           <id root="34c64c32-89c6-e0a0-e063-6394a90a8ddf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Vitamin Supplementation</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Initiate folic acid 400 mcg to 1000 mcg orally once daily, beginning 7 days before the first dose of pemetrexed for injection and continuing until 21 days after the last dose of pemetrexed for injection
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#s18">5.1</linkHtml>)]
  
   </content>.
 
  </item>
                                 <item>Administer vitamin B
  
   <sub>12,</sub>1 mg intramuscularly, 1 week prior to the first dose of pemetrexed for injection and every 3 cycles thereafter. Subsequent vitamin B
  
   <sub>12</sub>injections may be given the same day as treatment with pemetrexed for injection
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#s18">5.1</linkHtml>)]
  
   </content>.
  
   <content styleCode="bold">Do not substitute oral vitamin B</content>
                                    <content styleCode="bold">
                                       <sub>12</sub>
                                    </content>
                                    <content styleCode="bold">for intramuscular vitamin B</content>
                                    <content styleCode="bold">
                                       <sub>12</sub>
                                    </content>.
 
  </item>
                              </list>
                           </text>
                           <effectiveTime value="20250508"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s11">
                           <id root="34c64c32-89c7-e0a0-e063-6394a90a8ddf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Corticosteroids</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Administer dexamethasone 4 mg orally twice daily for three consecutive days, beginning the day before each pemetrexed for injection administration.</item>
                              </list>
                           </text>
                           <effectiveTime value="20250508"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s12">
                     <id root="34c64c32-89c8-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Dosage Modification of Ibuprofen in Patients with Mild to Moderate Renal Impairment Receiving Pemetrexed for injection</title>
                     <text>
                        <paragraph>In patients with creatinine clearances between 45 mL/min and 79 mL/min, modify administration of ibuprofen as follows
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#s23">5.6</linkHtml>), Drug Interactions (
  
   <linkHtml href="#s34">7</linkHtml>) and Clinical Pharmacology (
  
   <linkHtml href="#s57">12.3</linkHtml>)]
 
  </content>:

 </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Avoid administration of ibuprofen for 2 days before, the day of, and 2 days following administration of pemetrexed for injection.</item>
                           <item>Monitor patients more frequently for myelosuppression, renal, and gastrointestinal toxicity, if concomitant administration of ibuprofen cannot be avoided.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
               <component>
                  <section ID="s13">
                     <id root="34c64c32-89c9-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Dosage Modifications for Adverse Reactions</title>
                     <text>
                        <paragraph>Obtain complete blood count on Days 1, 8, and 15 of each cycle. Assess creatinine clearance prior to each cycle. Do not administer pemetrexed for injection if the creatinine clearance is less than 45 mL/min.</paragraph>
                        <paragraph>Delay initiation of the next cycle of pemetrexed for injection until:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>recovery of non-hematologic toxicity to Grade 0-2,</item>
                           <item>absolute neutrophil count (ANC) is 1500 cells/mm
  
   <sup>3</sup>or higher,
  
   <content styleCode="underline">and</content>
                           </item>
                           <item>platelet count is 100,000 cells/mm
  
   <sup>3</sup>or higher.
 
  </item>
                        </list>
                        <paragraph>Upon recovery, modify the dosage of pemetrexed for injection in the next cycle as specified in
 
  <linkHtml href="#t1">Table 1</linkHtml>.

 </paragraph>
                        <paragraph>For dosing modifications for cisplatin, carboplatin,  or  pembrolizumab, refer to their prescribing information .</paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" ID="t1" width="80%">
                           <caption>Table 1: Recommended Dosage Modifications for Adverse Reactions
  
   <footnote ID="Lbbd01535-8672-4079-a55e-b95017bb2f34">National Cancer Institute Common Toxicity Criteria for Adverse Events version 2 (NCI CTCAE v2)</footnote>
                           </caption>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Toxicity in Most Recent Treatment Cycle</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Pemetrexed for injection Dose Modification for Next Cycle</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" align="left" styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Myelosuppressive toxicity</content>
                                    <content styleCode="italics">[see Warnings and Precautions (
     
      <linkHtml href="#s18">5.1</linkHtml>)]
    
     </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">ANC less than 500/mm
    
     <sup>3</sup>
                                    <content styleCode="underline">
                                       <content styleCode="bold">and</content>
                                    </content>platelets greater than or equal to 50,000/mm
    
     <sup>3</sup>
                                    <br/>
                                    <content styleCode="underline">
                                       <content styleCode="bold">OR</content>
                                    </content>
                                    <br/>     Platelet count less than 50,000/mm
    
     <sup>3</sup>without bleeding. 
     <br/>
                                 </td>
                                 <td align="left" styleCode="Rrule" valign="middle">75% of previous dose 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">Platelet count less than 50,000/mm
    
     <sup>3</sup>with bleeding 
     <br/>
                                 </td>
                                 <td align="left" styleCode="Rrule" valign="middle">50% of previous dose 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">Recurrent Grade 3 or 4 myelosuppression after 2 dose reductions 
     <br/>
                                 </td>
                                 <td align="left" styleCode="Rrule" valign="middle">Discontinue 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" align="left" styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Non-hematologic toxicity</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">Any Grade 3 or 4 toxicities EXCEPT mucositis or neurologic toxicity 
     <br/>
                                    <content styleCode="underline">OR</content>
                                    <br/>     Diarrhea requiring hospitalization 
     <br/>
                                 </td>
                                 <td align="left" styleCode="Rrule" valign="middle">75% of previous dose 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">Grade 3 or 4 mucositis 
     <br/>
                                 </td>
                                 <td align="left" styleCode="Rrule" valign="middle">50% of previous dose 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">Renal toxicity
    
     <content styleCode="italics">[see Warnings and Precautions (
     
      <linkHtml href="#s19">5.2</linkHtml>)]
    
     </content>
                                    <br/>
                                 </td>
                                 <td align="left" styleCode="Rrule" valign="middle">Withhold until creatinine clearance is 45 mL/min or greater 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">Grade 3 or 4 neurologic toxicity 
     <br/>
                                 </td>
                                 <td align="left" styleCode="Rrule" valign="middle">Permanently discontinue 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">Recurrent Grade 3 or 4 non-hematologic toxicity after 2 dose reductions 
     <br/>
                                 </td>
                                 <td align="left" styleCode="Rrule" valign="middle">Permanently discontinue 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">Severe and life-threatening Skin Toxicity
    
     <content styleCode="italics">[see Warnings and Precautions (
     
      <linkHtml href="#s20">5.3</linkHtml>)]
    
     </content>
                                    <br/>
                                 </td>
                                 <td align="left" styleCode="Rrule" valign="middle">Permanently discontinue 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">Interstitial Pneumonitis
    
     <content styleCode="italics">[see Warnings and Precautions (
     
      <linkHtml href="#s21">5.4</linkHtml>)]
    
     </content>
                                    <br/>
                                 </td>
                                 <td align="left" styleCode="Rrule" valign="middle">Permanently discontinue 
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
               <component>
                  <section ID="s14">
                     <id root="34c64c32-89ca-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.7 Preparation for Administration</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Pemetrexed for injection is a  hazardous drug. Follow applicable special handling and disposal procedures.
  
   <sup>1</sup>
                           </item>
                           <item>Calculate the dose of pemetrexed for injection and determine the number of vials needed.</item>
                           <item>Reconstitute pemetrexed for injection to achieve a concentration of 25 mg/mL as follows:
  
   <list listType="unordered" styleCode="Disc">
                                 <item>Reconstitute each 100-mg vial with 4.2 mL of 0.9% Sodium Chloride Injection, USP (preservative-free)</item>
                                 <item>Reconstitute each 500-mg vial with 20 mL of 0.9% Sodium Chloride Injection, USP (preservative-free)</item>
                                 <item>Do not use calcium-containing solutions for reconstitution.</item>
                              </list>
                           </item>
                           <item>Gently swirl each vial until the powder is completely dissolved. The resulting solution is clear and ranges in color from colorless to yellow or green-yellow. FURTHER DILUTION IS REQUIRED prior to administration.</item>
                           <item>Store reconstituted, preservative-free product under refrigerated conditions [2-8°C (36-46°F)] for no longer than 24 hours from the time of reconstitution. Discard vial after 24 hours.</item>
                           <item>Inspect reconstituted product visually for particulate matter and discoloration prior to further dilution. If particulate matter is observed, discard vial.</item>
                           <item>Withdraw the calculated dose of pemetrexed for injection from the vial(s) and discard vial with any unused portion.</item>
                           <item>Further dilute pemetrexed for injection with 0.9% Sodium Chloride Injection (preservative-free) to achieve a total volume of 100 mL for intravenous infusion.</item>
                           <item>Store diluted, reconstituted product under refrigerated conditions [2-8°C (36-46°F)] for no more than 24 hours from the time of reconstitution. Discard after 24 hours.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s15">
               <id root="34c64c32-89cb-e0a0-e063-6394a90a8ddf"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>For injection: 100 mg or 500 mg pemetrexed for injection as a white to light-yellow or green-yellow lyophilized powder in single-dose vials for reconstitution.</paragraph>
               </text>
               <effectiveTime value="20250508"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>For Injection: 100 mg or 500 mg lyophilized powder in single-dose vial (
 
    <linkHtml href="#s15">3</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s16">
               <id root="34c64c32-89cc-e0a0-e063-6394a90a8ddf"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Pemetrexed for injection is contraindicated in patients with a history of severe hypersensitivity reaction to pemetrexed
 
  <content styleCode="italics">[see Adverse Reactions (
  
   <linkHtml href="#s26">6.1</linkHtml>)].
 
  </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250508"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <br/>  History of severe hypersensitivity reaction to pemetrexed. (
 
    <linkHtml href="#undefined">4</linkHtml>) 
    <br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s17">
               <id root="34c64c32-89cd-e0a0-e063-6394a90a8ddf"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250508"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Myelosuppression: Can cause severe bone marrow suppression resulting in cytopenia and an increased risk of infection. Do not administer pemetrexed for injection when the absolute neutrophil count is less than 1500 cells/mm
  
     <sup>3</sup>and platelets are less than 100,000 cells/mm
  
     <sup>3</sup>. Initiate supplementation with oral folic acid and intramuscular vitamin B
  
     <sub>12</sub>to reduce the severity of hematologic and gastrointestinal toxicity of pemetrexed for injection. (
  
     <linkHtml href="#s9">2.4</linkHtml>,
  
     <linkHtml href="#s18">5.1</linkHtml>)
 
    </item>
                           <item>Renal Failure: Can cause severe, and sometimes fatal, renal failure. Do not administer when creatinine clearance is less than 45 mL/min. (
  
     <linkHtml href="#s8">2.3</linkHtml>,
  
     <linkHtml href="#s19">5.2</linkHtml>)
 
    </item>
                           <item>Bullous and Exfoliative Skin Toxicity: Permanently discontinue for severe and life-threatening bullous, blistering or exfoliating skin toxicity. (
  
     <linkHtml href="#s20">5.3</linkHtml>)
 
    </item>
                           <item>Interstitial Pneumonitis: Withhold for acute onset of new or progressive unexplained pulmonary symptoms. Permanently discontinue if pneumonitis is confirmed. (
  
     <linkHtml href="#s21">5.4</linkHtml>)
 
    </item>
                           <item>Radiation Recall: Can occur in patients who received radiation weeks to years previously; permanently discontinue for signs of radiation recall. (
  
     <linkHtml href="#s22">5.5</linkHtml>)
 
    </item>
                           <item>Embryo-Fetal Toxicity: Can cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception. (
  
     <linkHtml href="#s24">5.7</linkHtml>,
  
     <linkHtml href="#s37">8.1</linkHtml>,
  
     <linkHtml href="#s43">8.3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s18">
                     <id root="34c64c32-89ce-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Myelosuppression and Increased Risk of Myelosuppression without Vitamin Supplementation</title>
                     <text>
                        <paragraph>
                           <br/>  Pemetrexed for injection can cause severe myelosuppression resulting in a requirement for transfusions and which may  lead to  neutropenic infection. The  risk  of  myelosuppression is increased in patients who do not receive vitamin  supplementation. In Study JMCH, incidences of Grade 3-4 neutropenia (38% versus 23%), thrombocytopenia (9% versus  5%), febrile neutropenia (9% versus 0.6%), and neutropenic infection (6% versus 0) were higher in patients who received pemetrexed  plus  cisplatin  without  vitamin  supplementation  as  compared  to  patients  who  were fully  supplemented with  folic acid and vitamin B
 
  <sub>12</sub> prior to and throughout pemetrexed plus cisplatin treatment. 
  <br/>  Initiate  supplementation  with  oral  folic  acid  and  intramuscular  vitamin  B
 
  <sub>12</sub> prior  to  the  first dose  of  pemetrexed;  continue  vitamin  supplementation  during  treatment  and  for 21 days after the last dose of pemetrexed to reduce the severity of hematologic and gastrointestinal  toxicity  of  pemetrexed  for  injection  [s
 
  <content styleCode="italics">ee  Dosage  and  Administration  (</content>
                           <content styleCode="italics">
                              <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark1">2.4</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>].  Obtain  a complete  blood  count  at  the  beginning  of  each  cycle.  Do  not  administer  pemetrexed  for injection  until  the  ANC  is  at  least  1500  cells/mm
 
  <sup>3</sup> and  platelet  count  is  at  least  100,000 cells/mm
 
  <sup>3</sup>. Permanently  reduce  pemetrexed  for  injection  in  patients  with  an  ANC  of  less  than 500  cells/mm
 
  <sup>3</sup> or  platelet  count  of  less  than  50,000  cells/mm
 
  <sup>3</sup> in  previous  cycles  [
 
  <content styleCode="italics">see  Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark2">2.6</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>]. 
  <br/>
                           <br/>  In Studies JMDB and JMCH, among patients who received vitamin supplementation, incidence of Grade 3-4 neutropenia  was  15%  and  23%,  the  incidence  of  Grade  3-4  anemia  was  6%  and  4%,  and  incidence of Grade 3-4 thrombocytopenia was  4% and 5%, respectively. In Study JMCH, 18% of patients in  the  pemetrexed for injection arm  required red  blood cell  transfusions  compared to 7%  of  patients  in the cisplatin arm [
 
  <content styleCode="italics">see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark6">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>]. In Studies JMEN, PARAMOUNT, and  JMEI,  where  all patients received vitamin supplementation, incidence of Grade 3-4 neutropenia ranged from 3% to 5%, and incidence of Grade 3-4 anemia ranged from 3% to 5%. 
  <br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
               <component>
                  <section ID="s19">
                     <id root="34c64c32-89cf-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Renal Failure</title>
                     <text>
                        <paragraph>
                           <br/>
                           <br/>  Pemetrexed for injection can cause severe, and sometimes fatal, renal toxicity. The incidences of renal  failure  in  clinical  studies  in  which  patients  received  pemetrexed  with  cisplatin  were:  2.1% in Study JMDB  and  2.2% in Study JMCH. The  incidence of renal failure in clinical studies in which patients  received  pemetrexed  as  a  single  agent  ranged  from  0.4%  to  0.6%  (Studies  JMEN, PARAMOUNT,  and  JMEI  [
 
  <content styleCode="italics">see  Adverse  Reactions  (6.1)</content>].   
  <br/>  Determine  creatinine  clearance  before each   dose   and   periodically   monitor   renal   function   during   treatment   with   pemetrexed   for   injection. 
  <br/>  Withhold  pemetrexed  for  injection  in  patients  with  a  creatinine  clearance  of  less  than  45 mL/minute [
 
  <content styleCode="italics">see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark1">2.3</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>].

 </paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
               <component>
                  <section ID="s20">
                     <id root="34c64c32-89d0-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Bullous and Exfoliative Skin Toxicity</title>
                     <text>
                        <paragraph>Serious and sometimes fatal, bullous, blistering and exfoliative skin toxicity, including cases suggestive of Stevens-Johnson Syndrome/Toxic epidermal necrolysis can occur with pemetrexed for injection. Permanently discontinue pemetrexed for injection for severe and life-threatening bullous, blistering or exfoliating skin toxicity.</paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
               <component>
                  <section ID="s21">
                     <id root="34c64c32-89d1-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Interstitial Pneumonitis</title>
                     <text>
                        <paragraph>Serious interstitial pneumonitis, including fatal cases, can occur with pemetrexed for injection treatment. Withhold pemetrexed for injection for acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, or fever pending diagnostic evaluation. If pneumonitis is confirmed, permanently discontinue pemetrexed.</paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
               <component>
                  <section ID="s22">
                     <id root="34c64c32-89d2-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Radiation Recall</title>
                     <text>
                        <paragraph>Radiation recall can occur with pemetrexed for injection in patients who have received radiation weeks to years previously. Monitor patients for inflammation or blistering in areas of previous radiation treatment. Permanently discontinue pemetrexed for injection for signs of radiation recall.</paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
               <component>
                  <section ID="s23">
                     <id root="34c64c32-89d3-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Increased Risk of Toxicity with Ibuprofen in Patients with Renal Impairment</title>
                     <text>
                        <paragraph>
                           <br/>  Exposure  to  pemetrexed  is  increased  in  patients  with  mild  to  moderate  renal impairment  who  take  concomitant  ibuprofen,  increasing  the  risks  of  adverse  reactions  of pemetrexed.  In  patients  with  creatinine  clearances  between  45  mL/min  and  79 mL/min,  avoid  administration  of  ibuprofen  for  2  days  before,  the  day  of,  and  2  days  following administration  of  pemetrexed.  If  concomitant  ibuprofen  use  cannot  be  avoided, monitor  patients  more  frequently  for  pemetrexed  adverse  reactions,  including myelosuppression,   renal,   and   gastrointestinal   toxicity  
 
  <content styleCode="italics">[see   Dosage   and   Administration   (</content>
                           <content styleCode="italics">
                              <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark1">2.5</linkHtml>
                           </content>
                           <content styleCode="italics">),</content>
                           <content styleCode="italics"/>
                           <content styleCode="italics">Drug</content>
                           <content styleCode="italics">Interactions (
  
   <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark9">7</linkHtml>
                           </content>
                           <content styleCode="italics">), and Clinical Pharmacology (
  
   <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark13">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
               <component>
                  <section ID="s24">
                     <id root="34c64c32-89d4-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Embryo-Fetal Toxicity</title>
                     <text>
                        <br/>
                        <paragraph>
                           <br/>  Based   on   findings   from   animal   studies   and   its   mechanism   of   action,   pemetrexed   can cause  fetal  harm  when  administered  to  a  pregnant  woman.  In  animal  reproduction  studies, intravenous  administration  of  pemetrexed  to  pregnant  mice  during  the  period  of  organogenesis was  teratogenic,  resulting  in  developmental  delays  and  increased  malformations  at  doses  lower than  the  recommended  human  dose  of  500  mg/m
 
  <sup>2</sup>.  Advise  pregnant  women  of  the  potential  risk to a fetus.  Advise  females  of  reproductive  potential  to  use  effective  contraception  during treatment  with  pemetrexed and  for  6  months  after  the last  dose.  Advise  males with  female  partners  of  reproductive  potential  to  use  effective  contraception  during  treatment with  pemetrexed and  for  3  months  after  the last  dose  
 
  <content styleCode="italics">[see  Use  in  Specific Populations (</content>
                           <content styleCode="italics">
                              <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark10">8.1, 8.3</linkHtml>
                           </content>
                           <content styleCode="italics">) and Clinical Pharmacology (
  
   <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark12">12.1</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s25">
               <id root="34c64c32-89d5-e0a0-e063-6394a90a8ddf"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions are discussed in greater detail in other sections of the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Myelosuppression
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#s18">5.1</linkHtml>)]
  
   </content>
                     </item>
                     <item>Renal failure
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#s19">5.2</linkHtml>)]
  
   </content>
                     </item>
                     <item>Bullous and exfoliative skin toxicity
  
   <content styleCode="italics">[see Warning and Precautions (
   
    <linkHtml href="#s20">5.3</linkHtml>)]
  
   </content>
                     </item>
                     <item>Interstitial pneumonitis
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#s21">5.4</linkHtml>)]
  
   </content>
                     </item>
                     <item>Radiation recall
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#s22">5.5</linkHtml>)]
  
   </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250509"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>The most common adverse reactions (incidence ≥20%) of pemetrexed for injection, when administered as a single agent are fatigue, nausea, and anorexia. (
  
     <linkHtml href="#s26">6.1</linkHtml>)
 
    </item>
                           <item>The most common adverse reactions (incidence ≥20%) of pemetrexed for injection when administered with cisplatin are vomiting, neutropenia, anemia, stomatitis/pharyngitis, thrombocytopenia, and constipation. (
  
     <linkHtml href="#s26">6.1</linkHtml>)
 
    </item>
                           <item>The most common adverse reactions (incidence ≥20%) of pemetrexed for injection when administered in combination with pembrolizumab and platinum chemotherapy are fatigue/asthenia, nausea, constipation, diarrhea, decreased appetite, rash, vomiting, cough, dyspnea, and pyrexia. (
  
     <linkHtml href="#s26">6.1</linkHtml>)
 
    </item>
                        </list>
                        <paragraph>To report SUSPECTED ADVERSE REACTIONS, contact Somerset Therapeutics, LLC at 1-800-417-9175 or FDA at 1-800-332-1088 or www.fda.gov/medwatch</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s26">
                     <id root="34c64c32-89d6-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <br/>
                        <paragraph>
                           <br/>  Because  clinical  trials  are  conducted  under  widely  varying  conditions,  adverse  reactions  rates cannot be directly  compared  to  rates  in  other  clinical  trials  and  may not  reflect  the  rates observed in clinical practice. 
  <br/>
                           <br/>  In  clinical  trials,  the  most  common adverse  reactions  (incidence  ≥20%)  of  pemetrexed for injection,  when administered as  a single  agent, are  fatigue,  nausea,  and anorexia. The  most  common adverse reactions (incidence ≥20%) of pemetrexed for injection, when  administered in combination with cisplatin are vomiting,  neutropenia,  anemia,  stomatitis/pharyngitis,  thrombocytopenia,  and  constipation.  The most  common  adverse  reactions  (incidence  ≥20%)  of  pemetrexed for injection,  when  administered  in combination  with  pembrolizumab  and  platinum  chemotherapy,  are  fatigue/asthenia,  nausea, constipation,  diarrhea,  decreased  appetite,  rash,  vomiting,  cough,  dyspnea,  and  pyrexia.
 </paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                     <component>
                        <section ID="s27">
                           <id root="34c64c32-89d7-e0a0-e063-6394a90a8ddf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Non-Squamous NSCLC</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250508"/>
                           <component>
                              <section ID="s28">
                                 <id root="34c64c32-89d8-e0a0-e063-6394a90a8ddf"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <br/>
                                    <br/>
                                    <br/>
                                    <br/>
                                    <paragraph>
                                       <content styleCode="italics">First-line Treatment of Metastatic Non-squamous NSCLC with Pembrolizumab and Platinum Chemotherapy</content>
                                    </paragraph>
                                    <paragraph>
                                       <br/>  The safety of pemetrexed for injection, in combination with pembrolizumab and investigator's choice of  platinum (either  carboplatin  or  cisplatin),  was  investigated  in  Study  KEYNOTE-189,  a  multicenter, double-blind, randomized (2:1), active-controlled  trial in patients with previously untreated, metastatic  non-squamous  NSCLC  with  no  EGFR  or ALK  genomic  tumor  aberrations.  A total  of 607  patients  received  pemetrexed for injection,  pembrolizumab,  and  platinum  every  3  weeks  for  4  cycles followed by pemetrexed for injection and pembrolizumab (n=405), or placebo, pemetrexed, and platinum every   3   weeks   for   4   cycles   followed   by   placebo   and   pemetrexed for injection   (n=202).   Patients   with   autoimmune disease that required systemic therapy within 2  years of treatment; a medical condition that required  immunosuppression;  or  who  had  received  more  than  30  Gy  of  thoracic radiation within the prior 26 weeks were  ineligible  [
 
  <content styleCode="italics">see  Clinical Studies  (</content>
                                       <content styleCode="italics">
                                          <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark14">14.1</linkHtml>
                                       </content>
                                       <content styleCode="italics">)</content>]. 
  <br/>  The  median  duration  of  exposure  to  pemetrexed for injection  was  7.2  months  (range:  1  day  to  1.7  years). Seventy-two percent of  patients received carboplatin.  The study population characteristics were median age of 64 years (range: 34 to 84), 49%  age  65  years  or  older,  59%  male,  94% White and 3%  Asian, and 18% with history of brain metastases at baseline. 
  <br/>
                                       <br/>  Pemetrexed for injection was discontinued for adverse reactions in 23% of patients in the pemetrexed for injection, pembrolizumab, and platinum  arm.  The most common adverse reactions resulting in discontinuation of pemetrexed in  this  arm  were  acute  kidney  injury  (3%) and  pneumonitis  (2%).  Adverse  reactions leading  to  interruption  of  pemetrexed  occurred  in  49%  of  patients  in  the  pemetrexed for injection, pembrolizumab, and platinum arm. The most common adverse reactions or laboratory abnormalities leading  to  interruption  of  pemetrexed for injection  in  this  arm  (≥2%)  were  neutropenia  (12%),  anemia  (7%),  asthenia (4%),  pneumonia  (4%),  thrombocytopenia  (4%),  increased  blood  creatinine  (3%),  diarrhea  (3%), and  fatigue (3%). 
  <br/>
                                       <br/>
                                       <br/>
                                       <br/>  Table  2  summarizes  the  adverse  reactions  that  occurred  in  ≥20%  of  patients  treated   with  pemetrexed for injection,   pembrolizumab,   and   platinum. 
  <br/>
                                       <br/>
                                    </paragraph>
                                    <table cellspacing="0" cellpadding="0" border="0" width="100%">
                                       <caption>Table 2: Adverse Reactions Occurring in ≥20% of Patients in KEYNOTE-189</caption>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top"/>
                                             <td colspan="2" align="center" styleCode="Rrule" valign="top">
                                                <br/>
                                                <content styleCode="bold">Pemetrexed for injection</content>
                                                <content styleCode="bold"/>
                                                <br/>
                                                <content styleCode="bold">Pembrolizumab</content>
                                                <content styleCode="bold"/>
                                                <br/>
                                                <content styleCode="bold">Platinum</content>
                                                <content styleCode="bold">Chemotherapy  </content>
                                                <content styleCode="bold">
                                                   <br/>  n=405
     </content>
                                                <br/>
                                             </td>
                                             <td colspan="2" align="center" styleCode="Rrule" valign="top">
                                                <content styleCode="bold">
                                                   <br/>  Placebo  
     </content>
                                                <content styleCode="bold">
                                                   <br/>  Pemetrexed for injection
     </content>
                                                <br/>
                                                <content styleCode="bold">Platinum Chemotherapy</content>
                                                <content styleCode="bold"/>
                                                <content styleCode="bold">
                                                   <br/>  n=202
     </content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">Adverse Reaction</content>
                                                <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">
                                                <content styleCode="bold">All Grades
     
      <footnote ID="fn87">Graded per NCI CTCAE version 4.03.</footnote>
                                                </content>
                                                <br/>
                                                <content styleCode="bold">(%)</content>
                                                <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">
                                                <content styleCode="bold">Grade 3-4</content>
                                                <br/>
                                                <content styleCode="bold">(%)</content>
                                                <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">
                                                <content styleCode="bold">All Grades</content>
                                                <br/>
                                                <content styleCode="bold">(%)</content>
                                                <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">
                                                <content styleCode="bold">Grade 3-4</content>
                                                <br/>
                                                <content styleCode="bold">(%)</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">Gastrointestinal Disorders</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Nausea 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">56 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">3.5 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">52 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">3.5 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Constipation 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">35 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">1.0 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">32 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0.5 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Diarrhea 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">31 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">5 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">21 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">3.0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Vomiting 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">24 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">3.7 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">23 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">3.0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">General Disorders and Administration Site Conditions</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Fatigue
    
     <footnote ID="L61f09536-a38f-464d-8a38-e8bf6da3efcd">Includes asthenia and fatigue.</footnote>
                                                <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">56 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">12 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">58 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">6 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Pyrexia 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">20 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0.2 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">15 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">Metabolism and Nutrition Disorders</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Decreased appetite 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">28 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">1.5 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">30 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0.5 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">Skin and Subcutaneous Tissue Disorders</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Rash
    
     <footnote ID="L2104fdc9-3e97-4524-8caa-7e8cf92ce7fd">Includes genital rash, rash, rash generalized, rash macular, rash maculo-papular, rash papular, rash pruritic, and rash pustular.</footnote>
                                                <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">25 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">2.0 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">17 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">2.5 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">Respiratory, Thoracic and Mediastinal Disorders</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Cough 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">21 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">28 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule" valign="top">Dyspnea 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">21 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">3.7 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">26 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">5 
     <br/>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>Table 3 summarizes the laboratory abnormalities that worsened from baseline in at least 20% of patients treated with pemetrexed for injection , pembrolizumab, and platinum.</paragraph>
                                    <table cellspacing="0" cellpadding="0" border="0" width="100%">
                                       <caption>Table 3: Laboratory Abnormalities Worsened from Baseline in ≥20% of Patients in KEYNOTE-189</caption>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top"/>
                                             <td colspan="2" align="center" styleCode="Rrule" valign="top">
                                                <br/>
                                                <content styleCode="bold">Pemetrexed for injection</content>
                                                <content styleCode="bold"/>
                                                <br/>
                                                <content styleCode="bold">Pembrolizumab</content>
                                                <content styleCode="bold"/>
                                                <content styleCode="bold">
                                                   <br/>  Platinum Chemotherapy
     </content>
                                                <br/>
                                             </td>
                                             <td colspan="2" styleCode="Rrule" valign="top">
                                                <content styleCode="bold">
                                                   <br/>  Placebo  
     </content>
                                                <br/>
                                                <content styleCode="bold">
                                                   <br/>  Pemetrexed for injection    
      <br/>  Platinum Chemotherapy
     </content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">Laboratory Te</content>
                                                <content styleCode="bold">st
     
      <footnote ID="fn95">Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: pemetrexed for injection/pembrolizumab/platinum chemotherapy (range: 381 to 401 patients) and placebo/ pemetrexed for injection/platinum chemotherapy (range: 184 to 197patients)</footnote>
                                                </content>
                                                <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">
                                                <content styleCode="bold">All Grades
     
      <footnote ID="L6931fb26-1000-4634-a344-5564252a2353">Graded per NCI CTCAE version 4.03.</footnote>
                                                </content>
                                                <br/>
                                                <content styleCode="bold">%</content>
                                                <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">
                                                <content styleCode="bold">Grades 3-4</content>
                                                <br/>
                                                <content styleCode="bold">%</content>
                                                <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">
                                                <content styleCode="bold">All Grades</content>
                                                <br/>
                                                <content styleCode="bold">%</content>
                                                <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">
                                                <content styleCode="bold">Grades 3-4</content>
                                                <br/>
                                                <content styleCode="bold">%</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">Chemistry</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Hyperglycemia 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">63 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">9 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">60 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">7 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Increased ALT 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">47 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">3.8 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">42 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">2.6 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Increased AST 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">47 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">2.8 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">40 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">1.0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Hypoalbuminemia 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">39 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">2.8 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">39 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">1.1 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Increased creatinine 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">37 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">4.2 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">25 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">1.0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Hyponatremia 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">32 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">7 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">23 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">6 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Hypophosphatemia 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">30 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">10 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">28 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">14 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Increased alkaline phosphatase 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">26 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">1.8 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">29 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">2.1 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Hypocalcemia 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">24 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">2.8 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">17 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0.5 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Hyperkalemia 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">24 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">2.8 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">19 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">3.1 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Hypokalemia 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">21 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">5 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">20 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">5 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">Hematology</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Anemia 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">85 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">17 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">81 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">18 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Lymphopenia 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">64 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">22 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">64 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">25 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Neutropenia 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">48 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">20 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">41 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">19 
     <br/>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule" valign="top">Thrombocytopenia 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">30 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">12 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">29 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">8 
     <br/>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <br/>
                                 </text>
                                 <effectiveTime value="20250508"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s29">
                                 <id root="34c64c32-89d9-e0a0-e063-6394a90a8ddf"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Initial Treatment in Combination with Cisplatin</content>
                                    </paragraph>
                                    <paragraph>
                                       <br/>  The safety of pemetrexed for injection was evaluated in Study JMDB, a randomized (1:1), open-label, multicenter trial conducted in  chemotherapy-naive patients with locally advanced or metastatic NSCLC. Patients received either pemetrexed for injection 500  mg/m
 
  <sup>2</sup>intravenously and cisplatin 75 mg/m
 
  <sup>2</sup>intravenously  on Day 1 of each 21-day cycle  (n=839) or gemcitabine  1250  mg/m
 
  <sup>2</sup>intravenously on Days 1  and  8  and  cisplatin  75  mg/m
 
  <sup>2</sup> intravenously  on  Day  1  of  each  21-day  cycle  (n=830).  All patients  were  fully  supplemented  with  folic  acid  and  vitamin   B
 
  <sub>12</sub>. 
  <br/>
                                       <br/>  Study JMDB excluded patients with an Eastern Cooperative Oncology Group Performance Status (ECOG PS  of  2  or  greater),  uncontrolled  third-space  fluid  retention,  inadequate  bone  marrow  reserve  and  organ function, or a calculated creatinine clearance less than 45 mL/min. Patients unable to stop using aspirin or  other  non-steroidal  anti-inflammatory  drugs  or  unable  to  take  folic  acid,  vitamin  B
 
  <sub>1</sub>
                                       <sub>2</sub> or  corticosteroids were also excluded from the study. 
  <br/>  The data described below reflect exposure to pemetrexed for injection plus cisplatin in 839 patients in Study JMDB. Median age was 61 years (range 26-83 years); 70% of patients were men; 78% were White,16% were Asian, 2.9% were Hispanic or Latino, 2.1% were Black or African American, and &lt;1% were  other  ethnicities;  36% had  an  ECOG  PS  0.  Patients received  a  median  of  5  cycles  of  pemetrexed. 
  <br/>
                                       <br/>
                                       <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark8">Table 4</linkHtml>provides the frequency and severity of adverse reactions that occurred in ≥5% of 839 patients receiving pemetrexed for injection in combination with cisplatin in Study JMDB. Study JMDB was not designed  to  demonstrate  a  statistically  significant  reduction  in  adverse  reaction  rates  for  pemetrexed for injection, as compared to the control arm, for any specified adverse reaction listed in Table 4.

 </paragraph>
                                    <table cellspacing="0" cellpadding="0" border="0" width="100%">
                                       <caption>Table 4: Adverse Reactions Occurring in ≥5% of Fully Vitamin-Supplemented Patients Receiving Pemetrexed in Combination with Cisplatin Chemotherapy in Study JMDB</caption>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td rowspan="2" styleCode="Lrule Rrule" valign="middle">
                                                <content styleCode="bold">
                                                   <br/>  Adverse Reaction
     
      <footnote ID="L23e74551-017b-43ab-9158-3eebb14f35ff">NCI CTCAE version 2.0</footnote>
                                                </content>
                                             </td>
                                             <td colspan="2" styleCode="Rrule" valign="middle">
                                                <content styleCode="bold">
                                                   <br/>  Pemetrexed for injection /  
     </content>
                                                <content styleCode="bold">
                                                   <br/>  Cisplatin   (N=839)
     </content>
                                             </td>
                                             <td colspan="2" styleCode="Rrule" valign="middle">
                                                <content styleCode="bold">
                                                   <br/>  Gemcitabine/Cisplatin
     </content>
                                                <content styleCode="bold">
                                                   <br/>  (N=830)
     </content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="center" styleCode="Lrule Rrule" valign="middle">
                                                <content styleCode="bold">All Grades</content>
                                                <br/>
                                                <content styleCode="bold">(%)</content>
                                                <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="middle">
                                                <content styleCode="bold">Grade 3-4</content>
                                                <br/>
                                                <content styleCode="bold">(%)</content>
                                                <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="middle">
                                                <content styleCode="bold">All Grades</content>
                                                <br/>
                                                <content styleCode="bold">(%)</content>
                                                <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="middle">
                                                <content styleCode="bold">Grade 3-4</content>
                                                <br/>
                                                <content styleCode="bold">(%)</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">All adverse reactions</content>
                                                <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">90 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">37 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">91 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">53 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold"> Laboratory</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">  Hematologic</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Anemia 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">33 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">6 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">46 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">10 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Neutropenia 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">29 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">15 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">38 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">27 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Thrombocytopenia 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">10 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">4 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">27 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">13 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">  Renal</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Elevated creatinine 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">10 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">1 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">7 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">1 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold"> Clinical</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">  Constitutional symptoms</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Fatigue 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">43 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">7 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">45 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">5 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">  Gastrointestinal</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Nausea 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">56 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">7 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">53 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">4 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Vomiting 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">40 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">6 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">36 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">6 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Anorexia 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">27 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">2 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">24 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">1 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Constipation 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">21 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">1 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">20 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Stomatitis/pharyngitis 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">14 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">1 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">12 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Diarrhea 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">12 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">1 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">13 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">2 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Dyspepsia/heartburn 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">5 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">6 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">  Neurology</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Sensory neuropathy 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">9 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">12 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">1 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Taste disturbance 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">8 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">9 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">  Dermatology/Skin</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Alopecia 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">12 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">21 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">1 
     <br/>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule" valign="top">Rash/Desquamation 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">7 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">8 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">1 
     <br/>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>The following additional adverse reactions of pemetrexed  were observed.</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Incidence 1% to &lt;5%</content>
                                       <br/>
                                       <content styleCode="italics">Body as a Whole —</content>febrile neutropenia, infection, pyrexia 
  <br/>
                                       <content styleCode="italics">General Disorders —</content>dehydration 
  <br/>
                                       <content styleCode="italics">Metabolism and Nutrition —</content>increased AST, increased ALT 
  <br/>
                                       <content styleCode="italics">Renal —</content>renal failure 
  <br/>
                                       <content styleCode="italics">Eye Disorder —</content>conjunctivitis

 </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Incidence &lt;1%</content>
                                       <br/>
                                       <content styleCode="italics">Cardiovascular —</content>arrhythmia 
  <br/>
                                       <content styleCode="italics">General Disorders —</content>chest pain 
  <br/>
                                       <content styleCode="italics">Metabolism and Nutrition —</content>increased GGT 
  <br/>
                                       <content styleCode="italics">Neurology —</content>motor neuropathy

 </paragraph>
                                 </text>
                                 <effectiveTime value="20250508"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s30">
                                 <id root="34c64c32-89da-e0a0-e063-6394a90a8ddf"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <br/>
                                    <br/>
                                    <br/>
                                    <br/>
                                    <br/>
                                    <br/>
                                    <br/>
                                    <br/>
                                    <paragraph>
                                       <br/>  Maintenance Treatment Following First-line Non-pemetrexed for injection Containing Platinum-Based Chemotherapy 
  <br/>
                                       <br/>
                                       <br/>  In Study JMEN, the safety of pemetrexed was evaluated in a randomized (2:1), placebo- controlled, multicenter trial conducted in patients with non-progressive locally advanced or metastatic NSCLC following four cycles of a first-line, platinum-based chemotherapy regimen. Patients received either pemetrexed 500 mg/m
 
  <sup>2</sup>or matching placebo intravenously every 21 days until disease progression or unacceptable toxicity. Patients in both study arms were fully supplemented with folic acid and vitamin B
 
  <sub>12</sub>. 
  <br/>
                                       <br/>
                                       <br/>
                                       <br/>
                                       <br/>
                                       <br/>  Study  JMEN excluded  patients  with an ECOG  PS  of 2  or  greater,  uncontrolled  third-space  fluid retention,  inadequate  bone  marrow  reserve  and  organ  function,  or  a  calculated  creatinine  clearance less  than  45  mL/min.  Patients  unable  to  stop  using  aspirin  or  other  non-steroidal  anti-inflammatory drugs or unable to take folic acid, vitamin B
 
  <sub>12</sub> or corticosteroids  were also excluded from the study. 
  <br/>
                                       <br/>  The   data   described   below   reflect   exposure   to   pemetrexed for injection   in   438   patients   in   Study   JMEN.   Median   age was   61   years   (range   26-83   years),   73%   of   patients   were   men;   65%   were   White,   31%   were   Asian,   2.9% were  Hispanic  or  Latino,  and  &lt;2% were  other ethnicities; 39% had an ECOG PS 0. Patients received a  median  of  5  cycles  of  pemetrexed for injection  and  a  relative  dose  intensity  of  pemetrexed for injection  of  96%. 
  <br/>  Approximately  half  the  patients  (48%)  completed  at  least  six,  21-day  cycles  and  23%  completed ten or more 21-day cycles of pemetrexed for injection. 
  <br/>
                                       <br/>
                                       <br/>
                                       <br/>  Table 5 provides the frequency and severity of adverse reactions reported in ≥5% of the 438 pemetrexed for injection-treated patients  in Study JMEN.
 
  <content styleCode="italics"/>
                                       <content styleCode="bold"/>
                                       <br/>
                                       <br/>
                                       <content styleCode="bold">Table 5: Adverse Reactions Occurring in </content>
                                       <content styleCode="bold">≥</content>
                                       <content styleCode="bold">5% of Patients Receiving Pemetrexed for injection in Study JMEN</content>
                                    </paragraph>
                                    <table cellspacing="0" cellpadding="0" border="0" width="100%">
                                       <col width=""/>
                                       <col width=""/>
                                       <col width=""/>
                                       <col width=""/>
                                       <col width=""/>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td rowspan="2" styleCode="Lrule Rrule" valign="middle">
                                                <content styleCode="bold">Adverse Reaction
     
      <footnote ID="K3614">NCI CTCAE version 3.0</footnote>
                                                </content>
                                                <br/>
                                             </td>
                                             <td colspan="2" align="center" styleCode="Rrule" valign="middle">
                                                <content styleCode="bold">
                                                   <br/>  Pemetrexed  for injection(N=438)
     </content>
                                                <br/>
                                             </td>
                                             <td colspan="2" align="center" styleCode="Rrule" valign="middle">
                                                <br/>
                                                <content styleCode="bold">Placebo</content>
                                                <content styleCode="bold">
                                                   <br/>  (N=218)
     </content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="middle">
                                                <content styleCode="bold">All Grades</content>
                                                <br/>
                                                <content styleCode="bold">(%)</content>
                                                <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="middle">
                                                <content styleCode="bold">Grade 3-4</content>
                                                <br/>
                                                <content styleCode="bold">(%)</content>
                                                <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="middle">
                                                <content styleCode="bold">All Grades</content>
                                                <br/>
                                                <content styleCode="bold">(%)</content>
                                                <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="middle">
                                                <content styleCode="bold">Grade 3-4</content>
                                                <br/>
                                                <content styleCode="bold">(%)</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">All adverse reactions</content>
                                                <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">66 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">16 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">37 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">4 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">Laboratory</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">Hematologic</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Anemia 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">15 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">3 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">6 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">1 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Neutropenia 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">6 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">3 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">Hepatic</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Increased ALT 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">10 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">4 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Increased AST 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">8 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">4 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">Clinical</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">Constitutional symptoms</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Fatigue 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">25 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">5 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">11 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">1 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">Gastrointestinal</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Nausea 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">19 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">1 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">6 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">1 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Anorexia 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">19 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">2 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">5 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Vomiting 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">9 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">1 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Mucositis/stomatitis 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">7 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">1 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">2 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Diarrhea 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">5 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">1 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">3 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Infection  
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">5 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">2 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">2 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">Neurology</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Sensory neuropathy 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">9 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">1 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">4 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">Dermatology/Skin</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule" valign="top">Rash/desquamation 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">10 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">3 
     <br/>
                                             </td>
                                             <td styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <br/>
                                    <br/>
                                    <paragraph>The  requirement  for  transfusions  (9.5%  versus  3.2%),  primarily  red  blood  cell  transfusions,  and for erythropoiesis  stimulating agents (5.9% versus 1.8%) were higher in  the pemetrexed for injection arm compared to the placebo arm. 
  <br/>
                                       <br/>  The following  additional  adverse  reactions  were  observed  in  patients  who  received   pemetrexed.
 </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">
                                          <br/>  Incidence 1% to &lt;5%
  </content>
                                       <br/>
                                       <content styleCode="italics">Dermatology/Skin — </content>alopecia, pruritus/itching 
  <br/>
                                       <content styleCode="italics">Gastrointestinal — </content>constipation 
  <br/>
                                       <content styleCode="italics">General Disorders — </content>edema, fever 
  <br/>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Hematologic — </content>thrombocytopenia 
  <br/>
                                       <content styleCode="italics">Eye Disorder —</content> ocular surface disease (including conjunctivitis), increased lacrimation

 </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">
                                          <br/>  Incidence &lt;1%
  </content>
                                       <br/>
                                       <content styleCode="italics">Cardiovascular — </content>supraventricular arrhythmia 
  <br/>
                                       <content styleCode="italics">Dermatology/Skin —</content> erythema multiforme 
  <br/>
                                       <content styleCode="italics">General Disorders — </content>febrile neutropenia, allergic reaction/hypersensitivity 
  <br/>
                                       <content styleCode="italics">Neurology — </content>motor neuropathy 
  <br/>
                                       <content styleCode="italics">Renal — </content>renal failure

 </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">
                                          <br/>  Maintenance Treatment Following First-line Pemetrexed Plus Platinum Chemotherapy
  </content>
                                    </paragraph>
                                    <paragraph>
                                       <br/>  The safety of pemetrexed was evaluated in PARAMOUNT, a randomized (2:1), placebo-  controlled  study  conducted  in  patients  with  non-squamous  NSCLC  with  non-progressive  (stable  or responding disease) locally advanced or metastatic  NSCLC following four cycles of pemetrexed in combination  with  cisplatin  as  first-line  therapy  for  NSCLC.  Patients  were  randomized  to  receive pemetrexed  500  mg/m
 
  <sup>2</sup> or  matching  placebo  intravenously  on Day  1  of each 21-day  cycle  until disease  progression  or  unacceptable  toxicity.  Patients  in  both  study  arms  received  folic  acid and vitamin   B
 
  <sub>12</sub>supplementation. 
  <br/>
                                       <br/>  PARAMOUNT  excluded  patients  with  an  ECOG  PS  of  2  or  greater,  uncontrolled  third-space  fluid retention, inadequate  bone marrow reserve and organ function, or a calculated creatinine clearance less  than  45  mL/min.  Patients  unable  to  stop  using  aspirin  or  other  non-steroidal  anti-inflammatory drugs or unable to take folic acid, vitamin B
 
  <sub>12</sub> or corticosteroids  were also excluded from the   study. 
  <br/>
                                       <br/>  The  data  described below  reflect exposure to pemetrexed in 333  patients  in PARAMOUNT. Median age was 61 years  (range 32 to 83 years);  58% of patients were  men; 94%  were  White, 4.8% were Asian, and &lt;1% were Black or African  American; 36% had an ECOG PS 0. The median number  of  maintenance  cycles  was  4  for  pemetrexed  and  placebo  arms.  Dose  reductions  for adverse reactions occurred in 3.3%  of  patients in  the  pemetrexed arm and  0.6%  in the  placebo arm.  Dose delays for adverse reactions occurred in 22% of patients in the pemetrexed arm and  16% in the placebo arm. 
  <br/>
                                       <br/>  Table 6 provides the frequency and severity of adverse reactions reported in ≥5% of the 333 pemetrexed-treated patients  in PARAMOUNT. 
  <br/>
                                       <br/>
                                       <br/>
                                       <br/>
                                       <content styleCode="bold">Table 6: Adverse Reactions Occurring in ≥5% of Patients Receiving Pemetrexed  in PARAMOUNT 
   <br/>
                                       </content>
                                       <br/>
                                    </paragraph>
                                    <table cellspacing="0" cellpadding="0" border="0" width="100%">
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td rowspan="2" styleCode="Lrule Rrule" valign="middle">
                                                <content styleCode="bold">Adverse Reaction
     
      <sup>a</sup>
                                                </content>
                                                <br/>
                                             </td>
                                             <td colspan="2" align="center" styleCode="Rrule" valign="top">
                                                <content styleCode="bold">Pemetrexed </content>
                                                <br/>
                                                <content styleCode="bold">(N=333)</content>
                                                <br/>
                                             </td>
                                             <td colspan="2" align="center" styleCode="Rrule" valign="top">
                                                <content styleCode="bold">Placebo</content>
                                                <br/>
                                                <content styleCode="bold">(N=167)</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="center" styleCode="Lrule Rrule" valign="bottom">
                                                <content styleCode="bold">All Grades</content>
                                                <br/>
                                                <content styleCode="bold">(%)</content>
                                                <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="bottom">
                                                <content styleCode="bold">Grade 3-4</content>
                                                <br/>
                                                <content styleCode="bold">(%)</content>
                                                <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="bottom">
                                                <content styleCode="bold">All Grades</content>
                                                <br/>
                                                <content styleCode="bold">(%)</content>
                                                <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="bottom">
                                                <content styleCode="bold">Grades 3-4</content>
                                                <br/>
                                                <content styleCode="bold">(%)</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">All adverse reactions</content>
                                                <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">53 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">17 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">34 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">4.8 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">Laboratory</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">Hematologic</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Anemia 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">15 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">4.8 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">4.8 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">0.6 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Neutropenia 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">9 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">3.9 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">0.6 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">Clinical</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">Constitutional symptoms</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Fatigue 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">18 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">4.5 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">11 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">0.6 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">Gastrointestinal</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Nausea 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">12 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">0.3 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">2.4 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Vomiting 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">6 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">1.8 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Mucositis/stomatitis 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">5 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">0.3 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">2.4 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">General disorders</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule" valign="top">Edema 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">5 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">3.6 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <br/>
                                    <paragraph>
                                       <sup>a</sup> NCI CTCAE version 3.0

 </paragraph>
                                    <paragraph>
                                       <br/>  The requirement for red blood cell (13% versus 4.8%) and platelet (1.5% versus 0.6%) transfusions, erythropoiesis stimulating agents (12% versus 7%), and granulocyte colony stimulating factors (6% versus 0%) were higher in the pemetrexed  arm compared to the placebo arm.
 </paragraph>
                                    <paragraph>
                                       <br/>  The following additional Grade 3 or 4 adverse reactions were observed more frequently in the pemetrexed arm.
 </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">
                                          <br/>  Incidence 1% to &lt;5%
  </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Blood/Bone Marrow</content> thrombocytopenia

 </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">General Disorders</content> febrile neutropenia

 </paragraph>
                                    <paragraph/>
                                    <paragraph>
                                       <content styleCode="bold">
                                          <br/>  Incidence &lt;1% 
   <br/>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Cardiovascular-</content> ventricular tachycardia, syncope

 </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">General Disorders-</content> pain

 </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Gastrointestinal-</content> gastrointestinal obstruction

 </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Neurologic</content> -depression

 </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Renal</content> -renal failure

 </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Vascular</content> -pulmonary embolism

 </paragraph>
                                    <paragraph/>
                                    <paragraph/>
                                 </text>
                                 <effectiveTime value="20250508"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s31">
                                 <id root="34c64c32-89db-e0a0-e063-6394a90a8ddf"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <br/>
                                    <br/>
                                    <paragraph>
                                       <content styleCode="italics">
                                          <br/>  Treatment of  Recurrent Disease  After  Prior   Chemotherapy
  </content>
                                       <br/>
                                       <br/>  The  safety  of  pemetrexed for injection  was  evaluated  in  Study  JMEI,  a  randomized  (1:1),  open-label,  active- controlled trial conducted  in patients who had progressed following platinum-based chemotherapy.  Patients  received  pemetrexed  500  mg/m
 
  <sup>2</sup> intravenously  or  docetaxel  75  mg/m
 
  <sup>2</sup>intravenously  on Day  1 of each  21-day  cycle.  All  patients  on the  pemetrexed for injection arm  received folic acid and vitamin B
 
  <sub>12</sub>supplementation. 
  <br/>
                                       <br/>  Study  JMEI  excluded  patients  with  an  ECOG  PS  of  3  or  greater,  uncontrolled third-space  fluid  retention, inadequate bone  marrow reserve and organ function, or a calculated creatinine clearance less  than  45  mL/min.  Patients  unable  to  discontinue  aspirin  or  other  non-steroidal  anti- inflammatory  drugs  or  unable  to  take  folic  acid,  vitamin  B
 
  <sub>12</sub> or  corticosteroids  were also excluded from the study. 
  <br/>
                                       <br/>  The  data  described  below  reflect  exposure  to  pemetrexed  for injection  in  265  patients  in  Study  JMEI.  Median  age was  58  years  (range  22 to 87 years); 73% of patients were men; 70% were  White, 24% were Asian, 2.6%  were  Black  or African  American,  1.8%  were Hispanic or Latino, and &lt;2% were other ethnicities; 19% had an ECOG PS 0. 
  <br/>
                                       <br/>  Table 7 provides the frequency and severity of adverse reactions reported in ≥5% of the 265 pemetrexed  for injection -treated patients  in Study JMEI. Study JMEI is not designed to demonstrate a statistically significant  reduction  in  adverse  reaction  rates  for  pemetrexed, as  compared to  the control  arm,  for any  specified  adverse  reaction  listed  in  the  Table  7  below.

 </paragraph>
                                    <table cellspacing="0" cellpadding="0" border="0" ID="t5" width="100%">
                                       <caption>Table  7:  Adverse  Reactions  Occurring  in  ≥5%  of  Fully  Supplemented  Patients  Receiving Pemetrexed  for injection  in Study JMEI</caption>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td rowspan="2" align="left" styleCode="Lrule Rrule" valign="middle">
                                                <content styleCode="bold">Adverse Reaction</content>
                                                <content styleCode="bold">
                                                   <sup>a</sup>
                                                </content>
                                                <br/>
                                             </td>
                                             <td colspan="2" align="center" styleCode="Rrule" valign="top">
                                                <br/>
                                                <content styleCode="bold">
                                                   <br/>  Pemetrexed for injection
     </content>
                                                <content styleCode="bold">(N=265)</content>
                                                <br/>
                                             </td>
                                             <td colspan="2" align="center" styleCode="Rrule" valign="top">
                                                <content styleCode="bold">Docetaxel</content>
                                                <br/>
                                                <content styleCode="bold">(N=276)</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="center" styleCode="Lrule Rrule" valign="top">
                                                <content styleCode="bold">All Grades</content>
                                                <br/>
                                                <content styleCode="bold">(%)</content>
                                                <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">
                                                <content styleCode="bold">Grades 3-4</content>
                                                <br/>
                                                <content styleCode="bold">(%)</content>
                                                <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">
                                                <content styleCode="bold">All Grade</content>
                                                <br/>
                                                <content styleCode="bold">(%)</content>
                                                <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">
                                                <content styleCode="bold">Grades 3-4</content>
                                                <br/>
                                                <content styleCode="bold">(%)</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" align="left" styleCode="Lrule Rrule" valign="middle">
                                                <content styleCode="bold">Laboratory</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" align="left" styleCode="Lrule Rrule" valign="middle">
                                                <content styleCode="bold">Hematologic</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Anemia 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">19 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">4 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">22 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">4 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Neutropenia 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">11 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">5 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">45 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">40 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Thrombocytopenia 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">8 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">2 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">1 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" align="left" styleCode="Lrule Rrule" valign="middle">
                                                <content styleCode="bold">Hepatic</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Increased ALT 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">8 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">2 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">1 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Increased AST 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">7 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">1 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">1 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" align="left" styleCode="Lrule Rrule" valign="middle">
                                                <content styleCode="bold">Clinical</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" align="left" styleCode="Lrule Rrule" valign="middle">
                                                <content styleCode="bold">Gastrointestinal</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Nausea 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">31 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">3 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">17 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">2 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Anorexia 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">22 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">2 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">24 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">3 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Vomiting 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">16 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">2 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">12 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">1 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Stomatitis/pharyngitis 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">15 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">1 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">17 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">1 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Diarrhea 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">13 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">0 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">24 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">3 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Constipation 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">6 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">0 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">4 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" align="left" styleCode="Lrule Rrule" valign="middle">
                                                <content styleCode="bold">Constitutional symptoms</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Fatigue 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">34 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">5 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">36 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">5 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Fever 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">8 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">0 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">8 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" align="left" styleCode="Lrule Rrule" valign="middle">
                                                <content styleCode="bold">Dermatology/Skin</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Rash/desquamation 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">14 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">0 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">6 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Pruritus 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">7 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">0 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">2 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Alopecia 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">6 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">1 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">38 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">2 
     <br/>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>
                                       <sup>a</sup>NCI CTCAE version 2.0.

 </paragraph>
                                    <paragraph>The following additional adverse reactions were observed in patients assigned to receive pemetrexed.</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">
                                          <br/>  Incidence 1% to &lt;5%
  </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Body as a Whole</content>— abdominal pain, allergic reaction/hypersensitivity, febrile neutropenia, infection

 </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Dermatology/Skin</content>— erythema multiforme

 </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Neurology</content>— motor neuropathy, sensory neuropathy

 </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">
                                          <br/>  Incidence &lt;1%
  </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Cardiovascular</content>— supraventricular arrhythmias

 </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Renal</content>— renal failure

 </paragraph>
                                 </text>
                                 <effectiveTime value="20250508"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s32">
                                 <id root="34c64c32-89dc-e0a0-e063-6394a90a8ddf"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline">Mesothelioma</content>
                                    </paragraph>
                                    <br/>
                                    <paragraph>
                                       <br/>  The  safety  of  pemetrexed for injection  was  evaluated  in  Study  JMCH,  a  randomized  (1:1),  single-blind  study conducted  in  patients  with  MPM  who  had  received  no  prior  chemotherapy  for  MPM.  Patients received pemetrexed 500 mg/m
 
  <sup>2</sup>intravenously in  combination with cisplatin 75 mg/m
 
  <sup>2</sup>intravenously on  Day  1 of each 21-day cycle or cisplatin 75  mg/m
 
  <sup>2</sup>intravenously  on  Day  1  of  each  21-day  cycle administered until  disease  progression or  unacceptable  toxicity. Safety  was assessed  in 226 patients   who   received   at   least   one   dose   of   pemetrexed   in   combination   with   cisplatin   and   222   patients who  received  at  least  one dose of cisplatin alone. Among 226 patients who received pemetrexed in combination with cisplatin, 74% (n=168)  received full supplementation with folic acid and vitamin B
 
  <sub>12</sub>during study therapy, 14% (n=32) were never supplemented,  and 12% (n=26) were partially supplemented. 
  <br/>  Study  JMCH  excluded  patients  with  Karnofsky  Performance  Scale  (KPS)  of  less  than  70, inadequate  bone  marrow  reserve  and  organ  function,  or  a  calculated  creatinine  clearance  less  than 45 mL/min. Patients unable to stop using aspirin  or  other non-steroidal anti-inflammatory drugs were also excluded from the study. 
  <br/>  The  data  described  below  reflect  exposure  to  pemetrexed  for injection  in  168  patients  that  were  fully  supplemented with folic acid and  vitamin B
 
  <sub>12</sub>. Median age was 60 years (range 19 to 85 years); 82% were men; 92%  were  White,  5%  were  Hispanic  or  Latino,  3.0%  were  Asian,  and  &lt;1%  were  other ethnicities; 54% had KPS of 90-100. The median number of treatment  cycles administered was 6  in the pemetrexed/cisplatin fully supplemented group and 2 in the pemetrexed/cisplatin never supplemented   group.   Patients   receiving   pemetrexed  for injection   in   the   fully   supplemented   group   had   a   relative dose intensity of 93%  of the protocol-specified pemetrexed dose intensity. The most common adverse reaction resulting in dose delay was  neutropenia. 
  <br/>  Table 8 provides the frequency and severity of adverse reactions ≥5% in the subgroup of pemetrexed  for injection  - treated patients who  were  fully  vitamin  supplemented  in  Study  JMCH. Study  JMCH  was  not  designed  to demonstrate  a  statistically  significant  reduction  in  adverse  reaction  rates  for  pemetrexed,  as compared  to  the  control  arm,  for  any  specified  adverse  reaction  listed  in  the  table  below.

 </paragraph>
                                    <table cellspacing="0" cellpadding="0" border="0" ID="t8" width="100%">
                                       <caption>Table  8:  Adverse  Reactions  Occurring  in  ≥5%  of  Fully  Supplemented  Subgroup  of  Patients Receiving  Pemetrexed  for injection  /Cisplatin in Study JMCH
  
   <sup>a</sup>
                                       </caption>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td rowspan="2" align="left" styleCode="Lrule Rrule" valign="middle">
                                                <content styleCode="bold">Adverse Reaction</content>
                                                <content styleCode="bold">
                                                   <sup>b</sup>
                                                </content>
                                                <br/>
                                             </td>
                                             <td colspan="2" align="center" styleCode="Rrule" valign="top">
                                                <content styleCode="bold">Pemetrexed for injection</content>
                                                <content styleCode="bold">/Cisplatin</content>
                                                <br/>
                                                <content styleCode="bold">(N=168)</content>
                                                <br/>
                                             </td>
                                             <td colspan="2" align="center" styleCode="Rrule" valign="top">
                                                <content styleCode="bold">Cisplatin</content>
                                                <br/>
                                                <content styleCode="bold">(N=163)</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="center" styleCode="Lrule Rrule" valign="middle">
                                                <content styleCode="bold">All Grades</content>
                                                <br/>
                                                <content styleCode="bold">(%)</content>
                                                <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">
                                                <content styleCode="bold">Grade 3-4</content>
                                                <br/>
                                                <content styleCode="bold">(%)</content>
                                                <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">
                                                <content styleCode="bold">All Grades</content>
                                                <br/>
                                                <content styleCode="bold">(%)</content>
                                                <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">
                                                <content styleCode="bold">Grade 3-4</content>
                                                <br/>
                                                <content styleCode="bold">(%)</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" align="left" styleCode="Lrule Rrule" valign="middle">
                                                <content styleCode="bold">Laboratory</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" align="left" styleCode="Lrule Rrule" valign="middle">
                                                <content styleCode="bold">Hematologic</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Neutropenia 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">56 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">23 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">13 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">3 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Anemia 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">26 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">4 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">10 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Thrombocytopenia 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">23 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">5 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">9 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" align="left" styleCode="Lrule Rrule" valign="middle">
                                                <content styleCode="bold">Renal</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Elevated creatinine 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">11 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">1 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">10 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">1 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Decreased creatinine clearance 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">16 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">1 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">18 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">2 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" align="left" styleCode="Lrule Rrule" valign="middle">
                                                <content styleCode="bold">Clinical</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" align="left" styleCode="Lrule Rrule" valign="middle">
                                                <content styleCode="bold">Eye Disorder</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Conjunctivitis 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">5 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">0 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">1 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" align="left" styleCode="Lrule Rrule" valign="middle">
                                                <content styleCode="bold">Gastrointestinal</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Nausea 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">82 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">12 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">77 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">6 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Vomiting 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">57 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">11 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">50 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">4 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Stomatitis/pharyngitis 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">23 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">3 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">6 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Anorexia 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">20 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">1 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">14 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">1 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Diarrhea 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">17 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">4 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">8 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Constipation 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">12 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">1 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">7 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">1 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Dyspepsia 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">5 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">1 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">1 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" align="left" styleCode="Lrule Rrule" valign="middle">
                                                <content styleCode="bold">Constitutional Symptoms</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Fatigue 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">48 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">10 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">42 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">9 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" align="left" styleCode="Lrule Rrule" valign="middle">
                                                <content styleCode="bold">Metabolism and Nutrition</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Dehydration 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">7 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">4 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">1 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">1 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" align="left" styleCode="Lrule Rrule" valign="middle">
                                                <content styleCode="bold">Neurology</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Sensory neuropathy 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">10 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">0 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">10 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">1 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Taste disturbance 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">8 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">0 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">6 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" align="left" styleCode="Lrule Rrule" valign="middle">
                                                <content styleCode="bold">Dermatology/Skin</content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Rash 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">16 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">1 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">5 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">0 
     <br/>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" styleCode="Lrule Rrule" valign="middle">Alopecia 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">11 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">0 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">6 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">0 
     <br/>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <br/>
                                    <sup>a</sup>
                                    <paragraph>In  Study JMCH, 226 patients received at least  one dose of  pemetrexed  for injection in combination with cisplatin and 222 patients  received  at least one dose of cisplatin. Table 8 provides the  ADRs for subgroup of patients treated with pemetrexed for injection in  combination  with cisplatin (168  patients) or cisplatin  alone  (163  patients) who received  full supplementation with  folic  acid and vitamin B
 
  <sub>12</sub>during study therapy. 
  <br/>
                                       <sup>b</sup> NCI  CTCAE version   2.0

 </paragraph>
                                    <paragraph>The following additional adverse reactions were observed in patients receiving pemetrexed for injection plus cisplatin:</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">
                                          <br/>  Incidence 1% to &lt;5%
  </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Body as a Whole</content>— febrile neutropenia, infection, pyrexia

 </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Dermatology/Skin</content>— urticaria

 </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">General Disorders</content>— chest pain

 </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism and Nutrition</content>— increased AST, increased ALT, increased GGT

 </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Renal</content>— renal failure

 </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">
                                          <br/>  Incidence &lt;1%
  </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Cardiovascular</content>— arrhythmia

 </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Neurology</content>— motor neuropathy

 </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">
                                          <br/>  Exploratory Subgroup Analyses based on Vitamin Supplementation
  </content>
                                    </paragraph>
                                    <paragraph>
                                       <br/>  Table 9 provides the results  of exploratory  analyses of the  frequency  and  severity  of NCI  CTCAE Grade 3 or 4 adverse  reactions  reported  in  more  pemetrexed for injection  -treated  patients  who  did  not receive vitamin supplementation (never  supplemented) as compared with those who received vitamin  supplementation  with  daily  folic  acid  and  vitamin  B
 
  <sub>12</sub>from  the  time  of  enrollment  in  Study JMCH (fully supplemented). 
  <br/>  Table  9:  Exploratory  Subgroup  Analysis  of  Selected  Grade  3/4  Adverse Reactions  Occurring in  Patients Receiving Pemetrexed  for injection  in  Combination  with  Cisplatin  with or without Full Vitamin Supplementation in Study JMCH
 
  <sup>a</sup>
                                    </paragraph>
                                    <table cellspacing="0" cellpadding="0" border="0" ID="t9" width="80%">
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="bottom">
                                                <content styleCode="bold">Grade 3-4 Adverse Reactions</content>
                                                <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">
                                                <content styleCode="bold">Fully Supplemented Patients</content>
                                                <br/>
                                                <content styleCode="bold">N=168 
      <br/>  (%)
     </content>
                                                <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="middle">
                                                <content styleCode="bold">Never Supplemented Patients</content>
                                                <br/>
                                                <content styleCode="bold">N=32 
      <br/>  (%)
     </content>
                                                <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="top">Neutropenia 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">23 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">38 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="top">Thrombocytopenia 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">5 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">9 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="top">Vomiting 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">11 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">31 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="top">Febrile neutropenia 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">1 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">9 
     <br/>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule" valign="top">Infection with Grade 3/4 neutropenia 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">0 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">6 
     <br/>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" styleCode="Lrule Rrule" valign="top">Diarrhea 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">4 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">9 
     <br/>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>
                                       <sup>a</sup>NCI CTCAE version 2.0

 </paragraph>
                                    <paragraph>The following adverse reactions occurred more frequently in patients who were fully vitamin supplemented than in patients who were never supplemented:</paragraph>
                                    <list listType="unordered" styleCode="Disc">
                                       <item>hypertension (11% versus 3%),</item>
                                       <item>chest pain (8% versus 6%),</item>
                                       <item>thrombosis/embolism (6% versus 3%).</item>
                                    </list>
                                    <paragraph>
                                       <content styleCode="underline">Additional Experience Across Clinical Trials</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Sepsis, with or without neutropenia, including fatal cases</content>: 1%

 </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Severe esophagitis, resulting in hospitalization:</content>&lt;1%

 </paragraph>
                                 </text>
                                 <effectiveTime value="20250508"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s33">
                     <id root="34c64c32-89dd-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of pemetrexed for injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Blood and Lymphatic System</content>— immune-mediated hemolytic anemia

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal</content>— colitis, pancreatitis

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">General Disorders and Administration Site Conditions</content>— edema

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Injury, poisoning, and procedural complications</content>— radiation recall

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory</content>— interstitial pneumonitis

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin</content>— Serious and fatal bullous skin conditions, Stevens-Johnson syndrome, and toxic epidermal necrolysis

 </paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s34">
               <id root="34c64c32-89de-e0a0-e063-6394a90a8ddf"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250508"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Ibuprofen increased risk of pemetrexed for injection toxicity in patients with mild to moderate renal impairment. Modify the ibuprofen dosage as recommended for patients with a creatinine clearance between 45 mL/min and 79 mL/min. (
 
    <linkHtml href="#s12">2.5</linkHtml>,
 
    <linkHtml href="#s23">5.6</linkHtml>,
 
    <linkHtml href="#s34">7</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s35">
                     <id root="34c64c32-89df-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Effects of Ibuprofen on Pemetrexed</content>
                        </paragraph>
                        <paragraph>Ibuprofen increases exposure (AUC) of pemetrexed
 
  <content styleCode="italics">[see Clinical Pharmacology (
  
   <linkHtml href="#s57">12.3</linkHtml>)]
 
  </content>. In patients with creatinine clearance between 45 mL/min and 79 mL/min:

 </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Avoid administration of ibuprofen for 2 days before, the day of, and 2 days following administration of pemetrexed for injection
  
   <content styleCode="italics">[see Dosage and Administration (
   
    <linkHtml href="#s12">2.5</linkHtml>)]
  
   </content>.
 
  </item>
                           <item>Monitor patients more frequently for myelosuppression, renal, and gastrointestinal toxicity, if concomitant administration of ibuprofen cannot be avoided.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s36">
               <id root="34c64c32-89e0-e0a0-e063-6394a90a8ddf"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250508"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Lactation: Advise not to breastfeed. (
 
    <linkHtml href="#s41">8.2</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s37">
                     <id root="34c64c32-89e1-e0a0-e063-6394a90a8ddf"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250508"/>
                     <component>
                        <section ID="s38">
                           <id root="34c64c32-89e2-e0a0-e063-6394a90a8ddf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>
                                 <br/>  Based on findings from animal studies and its mechanism of action, pemetrexed for injection can cause fetal  harm  when  administered  to  a  pregnant  woman  [
 
  <content styleCode="italics">see  Clinical  Pharmacology  (</content>
                                 <content styleCode="italics">
                                    <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark12">12.1</linkHtml>
                                 </content>
                                 <content styleCode="italics">)</content>].  There  are  no available  data on  pemetrexed for  injection  use  in  pregnant  women.  In  animal  reproduction studies, intravenous administration of pemetrexed to pregnant  mice during the period of  organogenesis was teratogenic, resulting in developmental delays and malformations at doses  lower than the recommended human dose of 500 mg/m
 
  <sup>2</sup>[
 
  <content styleCode="italics">see Data</content>].  Advise pregnant women of the potential risk  to  a  fetus  [
 
  <content styleCode="italics">see  Use  in  Special  Populations  (8.3)</content>]. 
  <br/>
                                 <br/>  In  the  U.S.  general  population,  the  estimated  background  risk  of  major  birth  defects  and  miscarriage  in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

 </paragraph>
                           </text>
                           <effectiveTime value="20250508"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s39">
                           <id root="34c64c32-89e3-e0a0-e063-6394a90a8ddf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250508"/>
                           <component>
                              <section ID="s40">
                                 <id root="34c64c32-89e4-e0a0-e063-6394a90a8ddf"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Pemetrexed was teratogenic in mice. Daily dosing of pemetrexed by intravenous injection to pregnant mice during the period of organogenesis increased the incidence of fetal malformations (cleft palate; protruding tongue; enlarged or misshaped kidney; and fused lumbar vertebra) at doses (based on BSA) 0.03 times the human dose of 500 mg/m
 
  <sup>2</sup>. At doses, based on BSA, greater than or equal to 0.0012 times the 500 mg/m
 
  <sup>2</sup>human dose, pemetrexed administration resulted in dose-dependent increases in developmental delays (incomplete ossification of talus and skull bone; and decreased fetal weight).

 </paragraph>
                                 </text>
                                 <effectiveTime value="20250508"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s41">
                     <id root="34c64c32-89e5-e0a0-e063-6394a90a8ddf"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20250508"/>
                     <component>
                        <section ID="s42">
                           <id root="34c64c32-89e6-e0a0-e063-6394a90a8ddf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There is no information regarding the presence of pemetrexed or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. Because of the potential for serious adverse reactions in breastfed infants from pemetrexed for injection, advise women not to breastfeed during treatment with pemetrexed for injection and for one week after last dose.</paragraph>
                           </text>
                           <effectiveTime value="20250508"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s43">
                     <id root="34c64c32-89e7-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>Based on animal data pemetrexed for injection can cause malformations and developmental delays when administered to a pregnant woman
 
  <content styleCode="italics">[see Use in Specific Populations (8.1)].</content>
                        </paragraph>
                        <paragraph>Pregnancy Testing</paragraph>
                        <paragraph>Verify pregnancy status of females of reproductive potential prior to initiating pemetrexed for injection
 
  <content styleCode="italics">[see Use in Specific Populations (8.1)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                     <component>
                        <section ID="s44">
                           <id root="34c64c32-89e8-e0a0-e063-6394a90a8ddf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Contraception</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250508"/>
                           <component>
                              <section ID="s45">
                                 <id root="34c64c32-89e9-e0a0-e063-6394a90a8ddf"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Females</content>
                                    </paragraph>
                                    <paragraph>Because of the potential for genotoxicity, advise females of reproductive potential to use effective contraception during treatment with pemetrexed for injection and for 6 months after the last dose.</paragraph>
                                 </text>
                                 <effectiveTime value="20250508"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s46">
                                 <id root="34c64c32-89ea-e0a0-e063-6394a90a8ddf"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Males</content>
                                    </paragraph>
                                    <paragraph>Because of the potential for genotoxicity, advise males with female partners of reproductive potential to use effective contraception during treatment with pemetrexed for injection and for 3 months after the last dose
 
  <content styleCode="italics">[see Nonclinical Toxicology (
  
   <linkHtml href="#s76">13.1</linkHtml>)]
 
  </content>.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20250508"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s47">
                           <id root="34c64c32-89eb-e0a0-e063-6394a90a8ddf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Infertility</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250508"/>
                           <component>
                              <section ID="s48">
                                 <id root="34c64c32-89ec-e0a0-e063-6394a90a8ddf"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Males</content>
                                    </paragraph>
                                    <paragraph>Pemetrexed for injection may impair fertility in males of reproductive potential. It is not known whether these effects on fertility are reversible
 
  <content styleCode="italics">[see Nonclinical Toxicology (
  
   <linkHtml href="#s76">13.1</linkHtml>)]
 
  </content>.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20250508"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s49">
                     <id root="34c64c32-89ed-e0a0-e063-6394a90a8ddf"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>
                           <br/>  The safety and effectiveness of pemetrexed for injection in pediatric patients have not been established. 
  <br/>
                           <br/>
                           <br/>  The safety and pharmacokinetics of pemetrexed for injection were evaluated in two clinical studies conducted in pediatric patients with recurrent solid tumors (NCT00070473 N=32 and NCT00520936 N=72). Patients in both studies received concomitant vitamin B12 and folic acid supplementation and dexamethasone. 
  <br/>
                           <br/>
                           <br/>  No tumor responses were observed. Adverse reactions observed in pediatric patients were similar to those observed in adults. 
  <br/>
                           <br/>
                           <br/>  Single-dose pharmacokinetics of pemetrexed were evaluated in 22 patients age 4 to 18 years enrolled in NCT00070473 were within range of values in adults.
 </paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
               <component>
                  <section ID="s50">
                     <id root="34c64c32-89ee-e0a0-e063-6394a90a8ddf"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <br/>
                        <paragraph>
                           <br/>  Of  the  3,946  patients  enrolled  in  clinical  studies  of  pemetrexed  for injection,  34%  were  65  and  over  and  4% were 75 and over. No  overall differences in effectiveness were observed between these patients and  younger patients. The incidences of Grade  3-4 anemia, fatigue, thrombocytopenia, hypertension, and neutropenia were higher in patients 65 years of age and older as  compared to younger patients: in at least one of five randomized  clinical trials. [
 
  <content styleCode="italics">see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark6">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">) and Clinical  Studies (</content>
                           <content styleCode="italics">
                              <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark14">14.1</linkHtml>
                           </content>
                           <content styleCode="italics">,  </content>
                           <content styleCode="italics">
                              <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark24">14.2</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>].

 </paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
               <component>
                  <section ID="s51">
                     <id root="34c64c32-89ef-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Patients with Renal Impairment</title>
                     <text>
                        <paragraph>
                           <br/>
                           <br/>  Pemetrexed for   injection   is   primarily   excreted   by the   kidneys. Decreased   renal   function results in reduced clearance and  greater exposure (AUC) to pemetrexed for injection compared with patients  with  normal  renal  function  [
 
  <content styleCode="italics">Warnings  and  Precautions  (</content>
                           <content styleCode="italics">
                              <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark4">5.2</linkHtml>
                           </content>
                           <content styleCode="italics">,  </content>
                           <content styleCode="italics">
                              <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark5">5.6</linkHtml>
                           </content>
                           <content styleCode="italics">)  and  Clinical  Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark13">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>].  No  dose  is  recommended  for  patients  with  creatinine  clearance  less  than  45  mL/min  [
 
  <content styleCode="italics">see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark1">2.3</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>].

 </paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s52">
               <id root="34c64c32-89f0-e0a0-e063-6394a90a8ddf"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>No drugs are approved for the treatment of pemetrexed for injection overdose. Based on animal studies, administration of leucovorin may mitigate the toxicities of pemetrexed for injection overdosage. It is not known whether pemetrexed is dialyzable.</paragraph>
               </text>
               <effectiveTime value="20250508"/>
            </section>
         </component>
         <component>
            <section ID="s53">
               <id root="34c64c32-89f1-e0a0-e063-6394a90a8ddf"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>
                     <br/>  Pemetrexed for injection USP is a folate analog metabolic inhibitor. The drug substance, pemetrexed disodium hemi- pentahydrate, has the chemical name L-glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4- oxo-1H-pyrrolo[2,3-d] pyrimidin-5yl) ethyl] benzoyl]-, Disodium, hemi-pentahydrate with a molecular formula of C
 
  <sub>20</sub>H
 
  <sub>19</sub>N
 
  <sub>5</sub>Na
 
  <sub>2</sub>O
 
  <sub>6</sub>2.5 H
 
  <sub>2</sub>O and a molecular weight of 516.37. The structural formula is as follows:
 
  <renderMultiMedia referencedObject="MM1"/>
                     <br/>  Pemetrexed for injection USP is a sterile white-to-light yellow or green-yellow lyophilized powder in single-dose vials to be reconstituted for intravenous infusion. Each 100-mg vial of pemetrexed for injection USP contains 100 mg pemetrexed (equivalent to 110.3 mg pemetrexed disodium hemi- pentahydrate) and 106 mg mannitol. Each 500 mg vial of pemetrexed for injection USP contains 500 mg pemetrexed (equivalent to 551.4 mg pemetrexed disodium hemi- pentahydrate) and 500 mg mannitol. Hydrochloric acid and/or sodium hydroxide may have been added to adjust pH.

 </paragraph>
               </text>
               <effectiveTime value="20250508"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Structural Formula </text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="pemetrexed-f01-v01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s54">
               <id root="34c64c32-89f2-e0a0-e063-6394a90a8ddf"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250508"/>
               <component>
                  <section ID="s55">
                     <id root="34c64c32-89f3-e0a0-e063-6394a90a8ddf"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <br/>
                        <paragraph>
                           <br/>
                           <br/>  Pemetrexed  for injection is a folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential  for  cell  replication.  In  vitro  studies  show  that  pemetrexed  inhibits  thymidylate  synthase  (TS), dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase (GARFT), which are folate- dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT.
 </paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
               <component>
                  <section ID="s56">
                     <id root="34c64c32-89f4-e0a0-e063-6394a90a8ddf"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Pemetrexed inhibited the in vitro growth of mesothelioma cell lines (MSTO-211H, NCI-H2052) and showed synergistic effects when combined with cisplatin.</paragraph>
                        <paragraph>Based on population pharmacodynamic analyses, the depth of the absolute neutrophil counts (ANC) nadir correlates with the systemic exposure to pemetrexed and supplementation with folic acid and vitamin B
 
  <sub>12</sub>. There is no cumulative effect of pemetrexed exposure on ANC nadir over multiple treatment cycles.

 </paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
               <component>
                  <section ID="s57">
                     <id root="34c64c32-89f5-e0a0-e063-6394a90a8ddf"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <effectiveTime value="20250508"/>
                     <component>
                        <section ID="s58">
                           <id root="34c64c32-89f6-e0a0-e063-6394a90a8ddf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>
                                 <br/>  The pharmacokinetics of pemetrexed when pemetrexed for injection was administered as a single agent in doses ranging from 0.2 to 838 mg/m
 
  <sup>2</sup>infused over a 10-minute period have been evaluated in 426 cancer patients  with  a  variety  of  solid tumors.  Pemetrexed  total  systemic  exposure  (AUC) and  maximum  plasma concentration (C
 
  <sub>max</sub>) increased proportionally with increase of dose. The pharmacokinetics of pemetrexed did not change over multiple treatment cycles.

 </paragraph>
                           </text>
                           <effectiveTime value="20250508"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s59">
                           <id root="34c64c32-89f7-e0a0-e063-6394a90a8ddf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>Pemetrexed has a steady-state volume of distribution of 16.1 liters. In vitro studies indicated that pemetrexed is 81% bound to plasma proteins.</paragraph>
                           </text>
                           <effectiveTime value="20250508"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s60">
                           <id root="34c64c32-89f8-e0a0-e063-6394a90a8ddf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min). As renal function decreases, the clearance of pemetrexed decreases and exposure (AUC) of pemetrexed increases.</paragraph>
                           </text>
                           <effectiveTime value="20250508"/>
                           <component>
                              <section ID="s61">
                                 <id root="34c64c32-89f9-e0a0-e063-6394a90a8ddf"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                    <paragraph>Pemetrexed is not metabolized to an appreciable extent.</paragraph>
                                 </text>
                                 <effectiveTime value="20250508"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s62">
                                 <id root="34c64c32-89fa-e0a0-e063-6394a90a8ddf"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Excretion</content>
                                    </paragraph>
                                    <paragraph>Pemetrexed is primarily eliminated in the urine, with 70% to 90% of the dose recovered unchanged within the first 24 hours following administration. In vitro studies indicated that pemetrexed is a substrate of OAT3 (organic anion transporter 3), a transporter that is involved in the active secretion of pemetrexed.</paragraph>
                                 </text>
                                 <effectiveTime value="20250508"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s63">
                           <id root="34c64c32-89fb-e0a0-e063-6394a90a8ddf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                              <paragraph>Age (26 to 80 years) and sex had no clinically meaningful effect on the systemic exposure of pemetrexed based on population pharmacokinetic analyses.</paragraph>
                           </text>
                           <effectiveTime value="20250508"/>
                           <component>
                              <section ID="s64">
                                 <id root="34c64c32-89fc-e0a0-e063-6394a90a8ddf"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Racial Groups</content>
                                    </paragraph>
                                    <paragraph>The pharmacokinetics of pemetrexed were similar in Whites and Blacks or African Americans. Insufficient data are available for other ethnic groups.</paragraph>
                                 </text>
                                 <effectiveTime value="20250508"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s65">
                                 <id root="34c64c32-89fd-e0a0-e063-6394a90a8ddf"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Hepatic Impairment</content>
                                    </paragraph>
                                    <paragraph>Pemetrexed has not been formally studied in patients with hepatic impairment. No effect of elevated AST, ALT, or total bilirubin on the PK of pemetrexed was observed in clinical studies.</paragraph>
                                 </text>
                                 <effectiveTime value="20250508"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s66">
                                 <id root="34c64c32-89fe-e0a0-e063-6394a90a8ddf"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>Pharmacokinetic analyses of pemetrexed included 127 patients with impaired renal function. Plasma clearance of pemetrexed decreases as renal function decreases, with a resultant increase in systemic exposure. Patients with creatinine clearances of 45, 50, and 80 mL/min had 65%, 54%, and 13% increases, respectively in systemic exposure (AUC) compared to patients with creatinine clearance of 100 mL/min
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#s8">2.3</linkHtml>) and Warnings and Precautions (
  
   <linkHtml href="#s19">5.2</linkHtml>)]
 
  </content>.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20250508"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s67">
                                 <id root="34c64c32-89ff-e0a0-e063-6394a90a8ddf"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Third-Space Fluid</content>
                                    </paragraph>
                                    <paragraph>The pemetrexed plasma concentrations in patients with various solid tumors with stable, mild to moderate third-space fluid were comparable to those observed in patients without third space fluid collections. The effect of severe third space fluid on pharmacokinetics is not known.</paragraph>
                                 </text>
                                 <effectiveTime value="20250508"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s68">
                           <id root="34c64c32-8a00-e0a0-e063-6394a90a8ddf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250508"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s69">
                           <id root="34c64c32-8a01-e0a0-e063-6394a90a8ddf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Drugs Inhibiting OAT3 Transporter</content>
                              </paragraph>
                              <paragraph>Ibuprofen, an OAT3 inhibitor, administered at 400 mg four times a day decreased the clearance of pemetrexed and increased its exposure (AUC) by approximately 20% in patients with normal renal function (creatinine clearance &gt;80 mL/min).</paragraph>
                           </text>
                           <effectiveTime value="20250508"/>
                           <component>
                              <section ID="s70">
                                 <id root="34c64c32-8a02-e0a0-e063-6394a90a8ddf"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">In Vitro Studies</content>
                                    </paragraph>
                                    <paragraph>Pemetrexed is a substrate for OAT3. Ibuprofen, an OAT3 inhibitor inhibited the uptake of pemetrexed in OAT3-expressing cell cultures with an average [I
 
  <sub>u</sub>]/IC
 
  <sub>50</sub>ratio of 0.38. In vitro data predict that at clinically relevant concentrations, other NSAIDs (naproxen, diclofenac, celocoxib) would not inhibit the uptake of pemetrexed by OAT3 and would not increase the AUC of pemetrexed to a clinically significant extent.
 
  <content styleCode="italics">[see Drug Interactions (
  
   <linkHtml href="#s34">7</linkHtml>)]
 
  </content>.

 </paragraph>
                                    <paragraph>Pemetrexed is a substrate for OAT4. In vitro, ibuprofen and other NSAIDs (naproxen, diclofenac, celecoxib) are not inhibitors of OAT4 at clinically relevant concentrations.</paragraph>
                                 </text>
                                 <effectiveTime value="20250508"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s71">
                                 <id root="34c64c32-8a03-e0a0-e063-6394a90a8ddf"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Aspirin</content>
                                    </paragraph>
                                    <paragraph>Aspirin, administered in low to moderate doses (325 mg every 6 hours), does not affect the pharmacokinetics of pemetrexed.</paragraph>
                                 </text>
                                 <effectiveTime value="20250508"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s72">
                                 <id root="34c64c32-8a04-e0a0-e063-6394a90a8ddf"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Cisplatin</content>
                                    </paragraph>
                                    <paragraph>Cisplatin does not affect the pharmacokinetics of pemetrexed and the pharmacokinetics of total platinum are unaltered by pemetrexed.</paragraph>
                                 </text>
                                 <effectiveTime value="20250508"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s73">
                                 <id root="34c64c32-8a05-e0a0-e063-6394a90a8ddf"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Vitamins</content>
                                    </paragraph>
                                    <paragraph>Neither folic acid nor vitamin B
 
  <sub>12</sub>affect the pharmacokinetics of pemetrexed.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20250508"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s74">
                                 <id root="34c64c32-8a06-e0a0-e063-6394a90a8ddf"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Drugs Metabolized by Cytochrome P450 Enzymes</content>
                                    </paragraph>
                                    <paragraph>In vitro studies suggest that pemetrexed does not inhibit the clearance of drugs metabolized by CYP3A, CYP2D6, CYP2C9, and CYP1A2.</paragraph>
                                 </text>
                                 <effectiveTime value="20250508"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s75">
               <id root="34c64c32-8a07-e0a0-e063-6394a90a8ddf"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250508"/>
               <component>
                  <section ID="s76">
                     <id root="34c64c32-8a08-e0a0-e063-6394a90a8ddf"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>No carcinogenicity studies have been conducted with pemetrexed. Pemetrexed was clastogenic in an in vivo micronucleus assay in mouse bone marrow but was not mutagenic in multiple in vitro tests (Ames assay, Chinese Hamster Ovary cell assay).</paragraph>
                        <paragraph>Pemetrexed administered intraperitoneally at doses of ≥0.1 mg/kg/day to male mice (approximately 0.0006 times the recommended human dose based on BSA) resulted in reduced fertility, hypospermia, and testicular atrophy.</paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s77">
               <id root="34c64c32-8a09-e0a0-e063-6394a90a8ddf"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20250508"/>
               <component>
                  <section ID="s78">
                     <id root="34c64c32-8a0a-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Non-Squamous NSCLC</title>
                     <effectiveTime value="20250508"/>
                     <component>
                        <section ID="s79">
                           <id root="34c64c32-8a0b-e0a0-e063-6394a90a8ddf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Initial Treatment in Combination with Pembrolizumab and Platinum</content>
                              </paragraph>
                              <paragraph>
                                 <br/>  The efficacy of pemetrexed for injection in combination with pembrolizumab and platinum chemotherapy was investigated in Study KEYNOTE-189 (NCT02578680), a randomized, multicenter, double-blind, active controlled trial conducted in patients with metastatic non-squamous NSCLC, regardless of PD-L1 tumor expression  status,  who  had  not  previously  received  systemic  therapy  for  metastatic  disease  and  in  whom there  were  no  EGFR  or  ALK  genomic  tumor  aberrations.  Patients  with  autoimmune  disease  that  required systemic therapy within 2 years of treatment; a medical condition that required immunosuppression; or who had received more than 30 Gy of thoracic radiation within the prior 26 weeks were ineligible. Randomization was stratified by smoking status (never versus former/current), choice of platinum (cisplatin  versus  carboplatin),  and  tumor  PD-L1  status  (TPS  &lt;1%  [negative]  versus  TPS  ≥1%).  Patients  were randomized (2:1) to one of the following treatment arms:
 </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Pemetrexed for injection 500 mg/m
  
   <sup>2</sup>, pembrolizumab 200 mg, and investigators choice of cisplatin 75 mg/m
  
   <sup>2</sup> or carboplatin AUC 5 mg/mL/min intravenously on Day 1 of each 21-day cycle for 4 cycles followed by pemetrexed IMTA 500 mg/m
  
   <sup>2</sup> and pembrolizumab 200 mg intravenously every 3 weeks. Pemetrexed was administered after pembrolizumab and prior to platinum chemotherapy on Day 1.
 
  </item>
                                 <item>Placebo, pemetrexed  for injection 500 mg/m
  
   <sup>2</sup>, and investigators choice of cisplatin 75 mg/m
  
   <sup>2</sup> or carboplatin AUC 5 mg/mL/min intravenously on Day 1 of each 21-day cycle for 4 cycles followed by placebo and pemetrexed  for injection 500 mg/m
  
   <sup>2</sup> intravenously every 3 weeks.
 
  </item>
                              </list>
                              <paragraph>
                                 <br/>  Treatment with pemetrexed for injection continued until RECIST v1.1 (modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ)-defined progression of disease as determined by the investigator or unacceptable toxicity. 
  <br/>
                                 <br/>  Patients randomized to placebo, pemetrexed, and platinum chemotherapy were offered pembrolizumab as a single agent at the time of disease progression. 
  <br/>
                                 <br/>  Assessment  of  tumor  status  was  performed  at  Week  6,  Week  12,  and  then  every  9  weeks  thereafter.  The main efficacy outcome  measures were OS and PFS as assessed by BICR RECIST v1.1, modified to follow a maximum  of  10  target  lesions  and  a  maximum  of  five  target  lesions  per  organ.  Additional  efficacy  outcome measures  were  ORR  and  duration  of  response,  as  assessed  by  the  BICR  according  to  RECIST  v1.1,  modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. 
  <br/>  A  total  of  616  patients  were  randomized:  410  patients  to  the  pemetrexed  for injection,  pembrolizumab,  and  platinum chemotherapy  arm  and  206  to  the  placebo,  pemetrexed  for injection,  and  platinum  chemotherapy  arm.  The   study population  characteristics  were:  median  age  of  64  years  (range:  34  to  84);  49%  age  65  or  older;  59%  male; 94% White and  3% Asian;  56%  ECOG performance status of  1;  and 18%  with history of  brain  metastases. 
  <br/>  Thirty-one percent had tumor PD-L1 expression TPS &lt;1%. Seventy-two percent received carboplatin and 12% were never smokers. A total of 85 patients in the placebo, pemetrexed for injection, and chemotherapy  arm  received  an  anti-PD-1/PD-L1  monoclonal  antibody  at  the  time  of  disease   progression. 
  <br/>
                                 <br/>  The trial demonstrated a statistically significant improvement in OS and PFS for patients randomized to pemetrexed in combination with pembrolizumab and platinum chemotherapy compared with placebo, pemetrexed for injection, and platinum chemotherapy (see Table 10 and
 
  <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark15">Figure 1</linkHtml>).

 </paragraph>
                              <paragraph>
                                 <br/>
                                 <content styleCode="bold">Table 10: Efficacy Results of KEYNOTE-189</content>
                              </paragraph>
                              <br/>
                              <table cellspacing="0" cellpadding="0" border="0" width="80%">
                                 <col width=""/>
                                 <col width=""/>
                                 <col width=""/>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">
                                          <content styleCode="bold">Endpoint</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>
                                          <content styleCode="bold">Pemetrexed for injection 
      <br/>  Pembrolizumab
     </content>
                                          <content styleCode="bold">
                                             <br/>  Platinum Chemotherapy n=410
     </content>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>
                                          <content styleCode="bold">Placebo</content>
                                          <content styleCode="bold">
                                             <br/>  Pemetrexed for injection 
     </content>
                                          <br/>
                                          <content styleCode="bold">Platinum Chemotherapy</content>
                                          <content styleCode="bold">
                                             <br/>  n=206
     </content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule" valign="top">
                                          <content styleCode="bold">OS</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">Number (%) of patients with event  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  127 (31%)  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  108 (52%)  
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="middle">Median in months (95% CI)  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  NR (NR, NR) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  11.3  
     <br/>  (8.7, 15.1)  
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">Hazard ratio
    
     <footnote ID="fn97">Based on the stratified Cox proportional hazard model.</footnote>(95% CI)  
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">
                                          <br/>  0.49 (0.38, 0.64)  
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">p-value
    
     <footnote ID="fn99">Based on stratified log-rank test.</footnote>
                                          <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">
                                          <br/>  &lt;0.0001  
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule" valign="top">
                                          <content styleCode="bold">PFS</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">Number of patients with event (%)  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  245 (60%)  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  166 (81%)  
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">Median in months (95% CI)  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  8.8 (7.6, 9.2) 
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  4.9 (4.7, 5.5)  
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">Hazard ratio
    
     <footnoteRef IDREF="fn97"/> (95% CI) 
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">
                                          <br/>  0.52 (0.43, 0.64)  
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">p-value
    
     <footnoteRef IDREF="fn99"/>
                                          <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">
                                          <br/>  &lt;0.0001  
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule" valign="top">
                                          <content styleCode="bold">ORR</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">Overall response rate
    
     <footnote ID="K8000">Response: Best objective response as confirmed complete response or partial response.</footnote> (95% CI)  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  48% (43, 53)  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  19% (14, 25)  
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">Complete response  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  0.5% 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  0.5%  
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">Partial response  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  47% 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  18%  
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">p-value
    
     <footnote ID="K8066">Based on Miettinen and Nurminen method stratified by PD-L1 status, platinum chemotherapy and smoking status.</footnote>
                                          <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">
                                          <br/>  &lt;0.0001  
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule" valign="top">
                                          <content styleCode="bold">Duration of Response</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule" valign="top">Median in months (range)  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  11.2 (1.1+, 18.0+)  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  7.8 (2.1+, 16.4+)  
     <br/>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph/>
                              <paragraph>
                                 <br/>  NR = not reached 
  <br/>
                                 <br/>  At the protocol specified final OS analysis, the median in the pemetrexed  for injection in combination with pembrolizumab and platinum chemotherapy arm was 22.0 months (95% CI: 19.5, 24.5) compared to 10.6 months (95% CI: 8.7, 13.6) in the placebo with pemetrexed  for injection and platinum chemotherapy arm, with an HR of 0.56 (95% CI: 0.46, 0.69). 
  <br/>
                                 <br/>
                                 <renderMultiMedia referencedObject="MM2"/>
                                 <br/>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Figure 1 : Kaplan-Meier Curve for Overall Survival in KEYNOTE-189</content>
                              </paragraph>
                              <paragraph>*Based on the protocol –specified final OS analysis
 
  <content styleCode="bold">
                                    <br/>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="underline">Initial Treatment in Combination with Cisplatin</content>
                              </paragraph>
                              <paragraph>The efficacy of pemetrexed for injection was evaluated in Study JMDB (NCT00087711), a multi-center, randomized (1:1),  open-label  study  conducted  in  1725  chemotherapy-naive  patients  with  Stage  IIIb/IV  NSCLC.  Patients were  randomized  to  receive  pemetrexed for injection with  cisplatin  or  gemcitabine  with  cisplatin.  Randomization  was stratified by Eastern Cooperative Oncology Group Performance Status (ECOG PS 0 versus 1), gender, disease stage, basis for pathological diagnosis (histopathological/cytopathological), history of brain metastases, and investigative center. Pemetrexed was administered intravenously over 10 minutes at a dose of 500  mg/m
 
  <sup>2</sup>on  Day 1 of each 21-day cycle. Cisplatin was administered intravenously at a dose of 75 mg/m
 
  <sup>2</sup>approximately 30 minutes after pemetrexed for injection administration on Day 1 of each cycle, gemcitabine was administered at a dose of 1250 mg/m
 
  <sup>2</sup>on Day 1 and Day 8, and cisplatin was administered intravenously at a dose of 75 mg/m
 
  <sup>2</sup>approximately 30 minutes after administration of gemcitabine,  on  Day  1  of  each  21-day  cycle.  Treatment  was  administered  up  to  a  total  of  6  cycles;  patients in  both  arms  received  folic  acid,  vitamin  B
 
  <sub>12</sub>,  and  dexamethasone  [see  Dosage  and  Administration (2.4)]. The primary efficacy outcome measure was overall survival. 
  <br/>  A  total  of  1725  patients  were  enrolled  with  862  patients  randomized  to  pemetrexed for injection  in  combination  with cisplatin and 863 patients to gemcitabine in combination with cisplatin. The median age was 61 years (range  26-83  years),  70%  were  male,  78%  were  White,  17%  were  Asian,  2.9%  were  Hispanic  or  Latino,  and 2.1%  were  Black  or  African  American,  and  &lt;1%  were  other  ethnicities.  Among  patients  for  whom  ECOG  PS (n=1722)  and  smoking  history  (n=1516)  were  collected,  65%  had  an  ECOG  PS  of  1,  36%  had  an  ECOG  PS  of 0, and 84% were smokers. For tumor characteristics, 73% had non- squamous NSCLC and 27% had squamous  NSCLC; 76%  had  Stage IV  disease.  Among  1252 patients  with non- squamous NSCLC  histology, 68%  had  a  diagnosis  of  adenocarcinoma,  12%  had  large  cell  histology  and  20%  had  other  histologic subtypes. 
  <br/>
                                 <br/>  Efficacy results in Study JMDB are presented in Table 11 and Figure 2.

 </paragraph>
                              <paragraph>
                                 <br/>
                              </paragraph>
                              <paragraph>
                                 <br/>
                                 <content styleCode="bold"/>
                                 <br/>
                                 <content styleCode="bold">
                                    <br/>
                                    <renderMultiMedia referencedObject="MM3"/>
                                    <br/>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">
                                    <renderMultiMedia referencedObject="MM4"/>
                                    <br/>
                                    <br/>  Figure 2 : Kaplan-Meier Curves for Overall Survival in Study JMDB
 
  </content>
                              </paragraph>
                              <br/>
                              <paragraph>In pre-specified analyses assessing the impact of NSCLC histology on overall survival, clinically relevant differences  in  survival  according  to  histology  were  observed.  These  subgroup  analyses  are  shown  in
 
  <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark16">Table 12</linkHtml>and
 
  <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark17">Figures 3</linkHtml>and
 
  <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark18">4</linkHtml>. This  difference in treatment effect for pemetrexed for injection based on histology  demonstrating  a  lack  of efficacy  in  squamous  cell  histology was also observed in Studies JMEN and JMEI.  

 </paragraph>
                              <paragraph>
                                 <br/>
                                 <content styleCode="bold">Table  12:  Overall  Survival  in  NSCLC  Histologic  Subgroups  in  Study JMDB</content>
                                 <content styleCode="bold">
                                    <br/>
                                    <renderMultiMedia referencedObject="MM5"/>
                                    <br/>
                                    <br/>
                                 </content>
                                 <br/>
                                 <content styleCode="bold"/>
                              </paragraph>
                              <paragraph/>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM6"/>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold"/>
                                 <content styleCode="bold">Figure 3</content>
                                 <content styleCode="bold">: Kaplan-Meier Curves for Overall Survival in Non-squamous NSCLC in Study JMDB 
   <br/>
                                    <br/>
                                    <renderMultiMedia referencedObject="MM7"/>
                                    <br/>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Figure 4 : Kaplan-Meier Curves for Overall Survival in Squamous NSCLC in Study JMDB</content>
                              </paragraph>
                              <paragraph/>
                           </text>
                           <effectiveTime value="20250508"/>
                           <component>
                              <observationMedia ID="MM2">
                                 <text>Figure 1</text>
                                 <value mediaType="image/jpeg" xsi:type="ED">
                                    <reference value="fig-1.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                           <component>
                              <observationMedia ID="MM3">
                                 <text>Table 11</text>
                                 <value mediaType="image/jpeg" xsi:type="ED">
                                    <reference value="table-11.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                           <component>
                              <observationMedia ID="MM4">
                                 <text>Figure 2</text>
                                 <value mediaType="image/jpeg" xsi:type="ED">
                                    <reference value="figure-2.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                           <component>
                              <observationMedia ID="MM5">
                                 <text>Table-12</text>
                                 <value mediaType="image/jpeg" xsi:type="ED">
                                    <reference value="table-12.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                           <component>
                              <observationMedia ID="MM6">
                                 <text>Figure 3</text>
                                 <value mediaType="image/jpeg" xsi:type="ED">
                                    <reference value="figure-3.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                           <component>
                              <observationMedia ID="MM7">
                                 <text>Figure 4</text>
                                 <value mediaType="image/jpeg" xsi:type="ED">
                                    <reference value="figure-4.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s80">
                           <id root="34c64c32-8a0c-e0a0-e063-6394a90a8ddf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Maintenance Treatment Following First-line Non-Pemetrexed for injection Containing Platinum-Based Chemotherapy</content>
                              </paragraph>
                              <paragraph>
                                 <br/>  The efficacy of pemetrexed as maintenance therapy following first-line platinum-based chemotherapy was evaluated in Study JMEN (NCT00102804), a multicenter, randomized (2:1), double-blind, placebo- controlled  study  conducted  in  663  patients  with  Stage  IIIb/IV  NSCLC  who  did  not  progress  after  four  cycles of platinum-based chemotherapy. Patients were  randomized to receive pemetrexed 500 mg/m
 
  <sup>2</sup>intravenously  every  21  days  or  placebo  until  disease  progression  or intolerable  toxicity.  Patients  in both study  arms  received  folic acid, vitamin  B
 
  <sub>12</sub>,  and dexamethasone  [
 
  <content styleCode="italics">see Dosage  and</content>
                                 <content styleCode="italics">Administration (</content>
                                 <content styleCode="italics">
                                    <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark1">2.4</linkHtml>
                                 </content>
                                 <content styleCode="italics">)</content>]. Randomization was carried out using a minimization approach [Pocock and Simon (1975)] using  the following factors: gender, ECOG PS (0 versus 1), response to prior chemotherapy (complete  or  partial  response  versus  stable  disease),  history  of  brain  metastases  (yes  versus  no), non-platinum  component  of  induction  therapy  (docetaxel  versus  gemcitabine  versus  paclitaxel),  and  disease  stage  (IIIb  versus  IV).  The  major  efficacy  outcome  measures  were  progression-free survival  based  on assessment by independent review  and overall survival; both  were  measured  from the date  of  randomization  in  Study  JMEN. 
  <br/>  A total of 663 patients were enrolled with 441 patients randomized to pemetrexed for injection and 222  patients randomized to  placebo. The median age was 61 years (range 26-83 years); 73% were  male; 65% were White, 32% were Asian, 2.9%  were Hispanic or Latino, and &lt;2% were other ethnicities; 60% had an  ECOG PS  of  1; and  73% were current or  former  smokers.  Median  time  from initiation of platinum-based chemotherapy to randomization was 3.3 months (range 1.6 to 5.1  months) and 49% of the population achieved a partial or complete response to first-line, platinum-based chemotherapy.  With regard to tumor  characteristics,  81% had  Stage IV  disease,  73% had  non-squamous NSCLC  and  27%  had  squamous  NSCLC.  Among  the  481  patients  with  non-squamous  NSCLC,  68%  had adenocarcinoma,  4%  had  large  cell,  and  28%  had  other  histologies.

 </paragraph>
                              <paragraph>Efficacy results are presented in Table 13 and Figure 5.</paragraph>
                              <table cellspacing="0" cellpadding="0" border="0" ID="t13" width="80%">
                                 <caption>Table 13: Efficacy Results in Study JMEN</caption>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="middle">
                                          <content styleCode="bold">Efficacy Parameter</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">
                                          <content styleCode="bold">Pemetrexed for injection</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">
                                          <content styleCode="bold">Placebo</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="middle">
                                          <content styleCode="bold">Overall survival</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">N=441 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">N=222 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="middle">Median (months) 
     <br/>          (95% CI) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">13.4 
     <br/>  (11.9-15.9) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">10.6 
     <br/>  (8.7-12.0) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="middle">Hazard ratio
    
     <sup>a</sup>
                                          <br/>          (95% CI) 
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">0.79 
     <br/>  (0.65-0.95) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="middle">p-value 
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">p=0.012 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="middle">
                                          <content styleCode="bold">Progression-free survival per independent review</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">N=387 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">N=194 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="middle">Median (months) 
     <br/>          (95% CI) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">4.0 
     <br/>  (3.1-4.4) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">2.0 
     <br/>  (1.5-2.8) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="middle">Hazard ratio
    
     <sup>a</sup>
                                          <br/>          (95% CI) 
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">0.60 
     <br/>  (0.49-0.73) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Lrule Rrule" valign="middle">p-value 
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">p&lt;0.00001 
     <br/>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>
                                 <sup>a</sup>Hazard ratios are adjusted for multiplicity but not for stratification variables.

 </paragraph>
                              <renderMultiMedia referencedObject="MM8"/>
                              <br/>
                              <paragraph>
                                 <content styleCode="bold">
                                    <br/>  Figure 5: Kaplan-Meier Curves for Overall Survival in Study JMEN
  </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">The results of pre-specified subgroup analyses by NSCLC histology are presented in  Table 14  and Figures 6 and  7 .</content>
                              </paragraph>
                              <table cellspacing="0" cellpadding="0" border="0" ID="t14" width="100%">
                                 <caption>Table 14: Efficacy Results in Study JMEN by Histologic Subgroup</caption>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="middle">
                                          <content styleCode="bold">Efficacy Parameter</content>
                                          <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Overall Survival</content>
                                          <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Progression-Free Survival</content>
                                          <br/>
                                          <content styleCode="bold">Per Independent Review</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="top"/>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Pemetrexed for injection</content>
                                          <br/>
                                          <content styleCode="bold">(N=441)</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Placebo</content>
                                          <br/>
                                          <content styleCode="bold">(N=222)</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Pemetrexed for injection</content>
                                          <br/>
                                          <content styleCode="bold">(N=387)</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Placebo</content>
                                          <br/>
                                          <content styleCode="bold">(N=194)</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="5" align="left" styleCode="Lrule Rrule" valign="middle">
                                          <content styleCode="bold">Non-squamous NSCLC (n=481)</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="top">Median (months) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="bottom">15.5 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="bottom">10.3 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="bottom">4.4 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="bottom">1.8 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="top">HR
    
     <sup>a</sup>
                                          <br/>          (95% CI) 
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">0.70 
     <br/>  (0.56-0.88) 
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">0.47 
     <br/>  (0.37-0.60) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="5" align="left" styleCode="Lrule Rrule" valign="middle">Adenocarcinoma (n=328) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="top">Median (months 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">16.8 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">11.5 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">4.6 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">2.7 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="top">HR
    
     <sup>a</sup>
                                          <br/>          (95% CI) 
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">0.73 
     <br/>  (0.56-0.96) 
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">0.51 
     <br/>  (0.38-0.68) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="5" align="left" styleCode="Lrule Rrule" valign="middle">Large cell carcinoma (n=20) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="top">Median (months) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">8.4 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">7.9 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">4.5 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">1.5 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="top">HR
    
     <sup>a</sup>
                                          <br/>          (95% CI) 
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">0.98 
     <br/>  (0.36-2.65) 
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">0.40 
     <br/>  (0.12-1.29) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="5" align="left" styleCode="Lrule Rrule" valign="middle">Other
    
     <sup>b</sup>(n=133) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="top">Median (months) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">11.3 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">7.7 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">4.1 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">1.6 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="top">HR
    
     <sup>a</sup>
                                          <br/>          (95% CI) 
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">0.61 
     <br/>  (0.40-0.94) 
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">0.44 (0.28-0.68) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="5" align="left" styleCode="Lrule Rrule" valign="middle">
                                          <content styleCode="bold">Squamous cell NSCLC (n=182)</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="top">Median (months) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">9.9 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">10.8 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">2.4 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">2.5 
     <br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Lrule Rrule" valign="top">HR
    
     <sup>a</sup>
                                          <br/>          (95% CI) 
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">1.07 
     <br/>  (0.77-1.50) 
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">1.03 
     <br/>  (0.71-1.49) 
     <br/>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>a Hazard ratios are not adjusted for multiplicity.</paragraph>
                              <paragraph>
                                 <sup>b</sup>Primary diagnosis of NSCLC not specified as adenocarcinoma, large cell carcinoma, or squamous cell carcinoma. 
  <br/>
                                 <br/>
                              </paragraph>
                              <renderMultiMedia referencedObject="MM9"/>
                              <br/>
                              <paragraph>
                                 <content styleCode="bold">Figure 6: Kaplan-Meier Curves for Overall Survival in Non-squamous NSCLC in Study JMEN</content>
                                 <br/>
                                 <br/>
                                 <renderMultiMedia referencedObject="MM10"/>
                                 <br/>
                                 <br/>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250508"/>
                           <component>
                              <observationMedia ID="MM8">
                                 <text>Figure 5</text>
                                 <value mediaType="image/jpeg" xsi:type="ED">
                                    <reference value="figure-5.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                           <component>
                              <observationMedia ID="MM9">
                                 <text>Figure 6</text>
                                 <value mediaType="image/jpeg" xsi:type="ED">
                                    <reference value="figure-6.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                           <component>
                              <observationMedia ID="MM10">
                                 <text>Figure 7</text>
                                 <value mediaType="image/jpeg" xsi:type="ED">
                                    <reference value="figure-7.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s81">
                           <id root="34c64c32-8a0d-e0a0-e063-6394a90a8ddf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Maintenance Treatment Following First-line Pemetrexed for injection Plus Platinum Chemotherapy</content>
                              </paragraph>
                              <paragraph>
                                 <br/>  The efficacy of pemetrexed as maintenance therapy following first-line platinum-based chemotherapy was also  evaluated in PARAMOUNT (NCT00789373), a multi-center, randomized (2:1),  double-blind,  placebo-  controlled  study  conducted  in  patients  with  Stage  IIIb/IV  non-squamous NSCLC  who  had  completed four cycles  of  pemetrexed in combination with cisplatin and achieved a complete response  (CR) or partial response (PR) or  stable  disease  (SD). Patients were required to have an ECOG PS of 0 or 1. Patients were randomized to receive  pemetrexed 500 mg/m
 
  <sup>2</sup>intravenously  every  21  days  or  placebo  until  disease  progression.  Randomization  was  stratified by  response  to  pemetrexed for injection  in  combination  with  cisplatin  induction  therapy  (CR  or  PR  versus SD),  disease stage (IIIb versus IV), and ECOG PS (0 versus 1). Patients in both arms received folic acid, vitamin B
 
  <sub>12</sub>,  and dexamethasone. The main efficacy outcome measure was investigator- assessed progression- free survival  (PFS) and an additional efficacy outcome measure was overall survival  (OS); PFS  and  OS were  measured from  the  time  of  randomization. 
  <br/>
                                 <br/>  A  total  of  539  patients  were  enrolled  with  359  patients  randomized  to  pemetrexed for injection  and  180  patients randomized  to  placebo.  The median  age  was  61  years  (range 32  to  83  years);  58% were  male; 95%  were White, 4.5% were  Asian,  and &lt;1% were Black or  African  American; 67% had an ECOG PS of 1; 78% were current or former smokers; and  43% of  the population achieved a partial or complete response to first-line, platinum-based chemotherapy. With  regard to tumor characteristics, 91% had Stage IV disease, 87%  had adenocarcinoma, 7%  had large cell,  and 6%  had other histologies. 
  <br/>
                                 <br/>  Efficacy  results for  PARAMOUNT  are  presented  in  
 
  <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark22">Table  15</linkHtml> and  
 
  <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark23">Figure 8.</linkHtml>
                              </paragraph>
                              <table cellspacing="0" cellpadding="0" border="0" ID="t15" width="80%">
                                 <caption>Table 15: Efficacy Results in PARAMOUNT</caption>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="middle">
                                          <content styleCode="bold">Efficacy Parameter</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Pemetrexed for injection</content>
                                          <br/>
                                          <content styleCode="bold">(N=359)</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Placebo</content>
                                          <br/>
                                          <content styleCode="bold">(N=180)</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" align="left" styleCode="Lrule Rrule" valign="middle">
                                          <content styleCode="bold">Overall survival</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="middle">Median (months) 
     <br/>          (95% CI) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">13.9 
     <br/>  (12.8-16.0) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">11.0 
     <br/>  (10.0-12.5) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="middle">Hazard ratio (HR)
    
     <sup>a</sup>
                                          <br/>          (95% CI) 
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">0.78 
     <br/>  (0.64-0.96) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="middle">p-value 
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">p=0.02 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" align="left" styleCode="Lrule Rrule" valign="middle">
                                          <content styleCode="bold">Progression-free survival</content>
                                          <content styleCode="bold">
                                             <sup>b</sup>
                                          </content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="middle">Median (months) 
     <br/>          (95% CI) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">4.1 
     <br/>  (3.2-4.6) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">2.8 
     <br/>  (2.6-3.1) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="middle">Hazard ratio (HR)
    
     <sup>a</sup>
                                          <br/>          (95% CI) 
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">0.62 
     <br/>  (0.49-0.79) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Lrule Rrule" valign="middle">p-value 
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">p&lt;0.0001 
     <br/>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>a Hazard ratios are adjusted for multiplicity but not for stratification variables.</paragraph>
                              <paragraph>
                                 <sup>b</sup>Based on investigator's assessment.

 </paragraph>
                              <renderMultiMedia referencedObject="MM11"/>
                              <br/>
                              <paragraph>
                                 <content styleCode="bold">
                                    <br/>  Figure 8: Kaplan-Meier Curves for Overall Survival in PARAMOUNT
  </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250508"/>
                           <component>
                              <observationMedia ID="MM11">
                                 <text>Figure 8</text>
                                 <value mediaType="image/jpeg" xsi:type="ED">
                                    <reference value="figure-8.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s82">
                           <id root="34c64c32-8a0e-e0a0-e063-6394a90a8ddf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Treatment of Recurrent Disease After Prior Chemotherapy</content>
                              </paragraph>
                              <br/>
                              <paragraph>
                                 <br/>  The efficacy of pemetrexed for injection was evaluated in Study JMEI (NCT00004881), a multicenter, randomized (1:1),  open-  label  study  conducted  in  patients  with  Stage  III  or  IV  NSCLC  that  had  recurred  or  progressed following one prior  chemotherapy regimen for advanced disease. Patients were randomized to  receive  pemetrexed  500  mg/m
 
  <sup>2</sup>intravenously  or  docetaxel  75  mg/m
 
  <sup>2</sup>as  a  1-hour  intravenous infusion  once  every  21  days.  Patients  randomized  to  pemetrexed  also  received  folic  acid  and vitamin  B
 
  <sub>12</sub>.  The  study  was  designed  to  show  that  overall  survival  with  pemetrexed for injection  was  non- inferior to  docetaxel,  as the major efficacy  outcome measure, and  that overall survival was superior for patients randomized to pemetrexed compared to docetaxel, as a secondary outcome measure. 
  <br/>
                                 <br/>
                                 <br/>  A   total   of   571   patients   were   enrolled   with   283   patients   randomized   to   pemetrexed for injection and   288   patients randomized to  docetaxel. The median age was 58 years (range 22 to 87 years); 72% were male; 71% were White, 24% were  Asian, 2.8% were Black or African American, 1.8% were Hispanic or Latino, and &lt;2% were other ethnicities; 88%  had an ECOG PS of 0 or 1. With regard to tumor characteristics, 75% had Stage IV disease; 53% had  adenocarcinoma, 30% had squamous histology;  8%  large  cell;  and 9%  had other  histologic  subtypes  of NSCLC. 
  <br/>
                                 <br/>   The efficacy results in  the  overall population and in  subgroup analyses based  on histologic subtype are provided  in  Tables  16  and  17,  respectively.  Study  JMEI  did  not  show  an  improvement  in  overall  survival in the intent-to-treat  population. In subgroup analyses, there was no evidence of a treatment effect  on survival in  patients with  squamous NSCLC; the absence of a treatment effect in  patients with NSCLC of squamous histology was also  observed Studies JMDB and JMEN [
 
  <content styleCode="italics">see Clinical Studies (</content>
                                 <content styleCode="italics">
                                    <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark14">14.1</linkHtml>
                                 </content>
                                 <content styleCode="italics">)</content>].

 </paragraph>
                              <table cellspacing="0" cellpadding="0" border="0" ID="t16" width="80%">
                                 <caption>Table 16: Efficacy Results in Study JMEI</caption>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="middle">
                                          <content styleCode="bold">Efficacy Parameter</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">
                                          <content styleCode="bold">Pemetrexed for injection</content>
                                          <br/>
                                          <content styleCode="bold">(N=283)</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">
                                          <content styleCode="bold">Docetaxel</content>
                                          <br/>
                                          <content styleCode="bold">(N=288)</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" align="left" styleCode="Lrule Rrule" valign="middle">
                                          <content styleCode="bold">Overall survival</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="top">Median (months) 
     <br/>          (95% CI) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">8.3 
     <br/>  (7.0-9.4) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">7.9 
     <br/>  (6.3-9.2) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="top">Hazard ratio
    
     <sup>a</sup>
                                          <br/>          (95% CI) 
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">0.99 
     <br/>  (0.82-1.20) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" align="left" styleCode="Lrule Rrule" valign="middle">
                                          <content styleCode="bold">Progression-free survival</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="top">Median (months) 
     <br/>          (95% CI) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">2.9 
     <br/>  (2.4-3.1) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">2.9 
     <br/>  (2.7-3.4) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="top">Hazard ratio
    
     <sup>a</sup>
                                          <br/>          (95% CI) 
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">
                                          <br/>   0.97 
     <br/>  (0.82-1.16)
    </td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Lrule Rrule" valign="top">
                                          <content styleCode="bold">Overall response rate</content>
                                          <br/>          (95% CI) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">8.5% 
     <br/>  (5.2-11.7) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">8.3% 
     <br/>  (5.1-11.5) 
     <br/>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>
                                 <sup>a</sup>Hazard ratios are not adjusted for multiplicity or for stratification variables.

 </paragraph>
                              <table cellspacing="0" cellpadding="0" border="0" ID="t17" width="80%">
                                 <caption>Table 17: Exploratory Efficacy Analyses by Histologic Subgroup in Study JMEI</caption>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="middle">
                                          <content styleCode="bold">Histologic Subgroups</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Pemetrexed for injection</content>
                                          <br/>
                                          <content styleCode="bold">(N=283)</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Docetaxel</content>
                                          <br/>
                                          <content styleCode="bold">(N=288)</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" align="left" styleCode="Lrule Rrule" valign="top">
                                          <content styleCode="bold">Non-squamous NSCLC (N=399)</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="top">Median (months) 
     <br/>          (95% CI) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">9.3 
     <br/>  (7.8-9.7) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">8.0 
     <br/>  (6.3-9.3) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="top">HR
    
     <sup>a</sup>
                                          <br/>          (95% CI) 
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">0.89 
     <br/>  (0.71-1.13) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" align="left" styleCode="Lrule Rrule" valign="top">Adenocarcinoma (N=301) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="top">Median (months) 
     <br/>          (95% CI) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">9.0 
     <br/>  (7.6-9.6) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">9.2 
     <br/>  (7.5-11.3) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="top">HR
    
     <sup>a</sup>
                                          <br/>          (95% CI) 
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">1.09 
     <br/>  (0.83-1.44) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" align="left" styleCode="Lrule Rrule" valign="top">Large Cell (N=47) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="top">Median (months) 
     <br/>          (95% CI) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">12.8 
     <br/>  (5.8-14.0) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">4.5 
     <br/>  (2.3-9.1) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="top">HR
    
     <sup>a</sup>
                                          <br/>          (95% CI) 
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">0.38 
     <br/>  (0.18-0.78) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" align="left" styleCode="Lrule Rrule" valign="top">Other
    
     <sup>b</sup>(N=51) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="top">Median (months) 
     <br/>          (95% CI) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">9.4 
     <br/>  (6.0-10.1) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">7.9 
     <br/>  (4.0-8.9) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="top">HR
    
     <sup>a</sup>
                                          <br/>          (95% CI) 
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">0.62 
     <br/>  (0.32-1.23) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" align="left" styleCode="Lrule Rrule" valign="top">
                                          <content styleCode="bold">Squamous NSCLC (N=172)</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="top">Median (months) 
     <br/>          (95% CI) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">6.2 
     <br/>  (4.9-8.0) 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">7.4 
     <br/>  (5.6-9.5) 
     <br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Lrule Rrule" valign="top">HR
    
     <sup>a</sup>
                                          <br/>          (95% CI) 
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">1.32 
     <br/>  (0.93-1.86) 
     <br/>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>a Hazard ratio unadjusted for multiple comparisons</paragraph>
                              <paragraph>
                                 <sup>b</sup>Primary diagnosis of NSCLC not specified as adenocarcinoma, large cell carcinoma, or squamous cell carcinoma.

 </paragraph>
                           </text>
                           <effectiveTime value="20250508"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s83">
                     <id root="34c64c32-8a0f-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Mesothelioma</title>
                     <text>
                        <paragraph>
                           <br/>  The efficacy of pemetrexed for injection was evaluated in Study JMCH (NCT00005636), a multicenter, randomized (1:1),  single-blind study conducted in patients with MPM who had received no prior chemotherapy.  Patients  were  randomized  (n=456)  to  receive  pemetrexed  500  mg/m
 
  <sup>2</sup> intravenously over   10   minutes   followed   30   minutes   later   by   cisplatin   75   mg/m
 
  <sup>2</sup>  intravenously   over   two   hours   on   Day 1  of  each  21-day  cycle  or  to  receive  cisplatin  75  mg/m
 
  <sup>2</sup> intravenously over 2  hours on  Day 1 of  each 21-day  cycle;  treatment  continued  until  disease  progression  or  intolerable  toxicity.  The  study was  modified  after  randomization  and  treatment  of  117  patients  to  require  that  all  patients  receive folic  acid  350  mcg  to  1000  mcg  daily  beginning  1  to  3  weeks  prior  to  the  first  dose  of  pemetrexed for injection and continuing  until  1  to  3  weeks  after  the  last  dose,  vitamin  B
 
  <sub>12</sub> 1000  mcg  intramuscularly  1  to  3  weeks prior to first dose of pemetrexed for injection and every 9 weeks thereafter, and dexamethasone 4 mg orally, twice daily, for 3 days starting the day prior to each pemetrexed dose. Randomization was  stratified by multiple baseline variables including KPS, histologic subtype (epithelial, mixed, sarcomatoid, other), and gender. The major efficacy outcome measure was overall survival and additional efficacy outcome  measures were time to disease  progression, overall response rate,  and response duration. 
  <br/>  A  total of 448 patients received at least one dose of protocol-specified therapy; 226 patients were randomized  to  and  received  at  least  one  dose  of  pemetrexed  plus  cisplatin,  and  222  patients were randomized to and received  cisplatin. Among the 226 patients who received cisplatin with pemetrexed for injection, 74% received full supplementation  with folic acid and vitamin B
 
  <sub>12 </sub>during study therapy, 14% were never supplemented, and 12% were partially  supplemented. Across the study population, the median age was 61 years (range: 20 to 86 years); 81% were male;  92%  were  White,  5% were Hispanic or Latino, 3.1% were Asian, and &lt;1% were other ethnicities; and 54% had a  baseline KPS score of 90-100% and 46% had a KPS score of 70-80%. With regard to tumor characteristics, 46% had Stage IV disease, 31% Stage III, 15% Stage II, and 7% Stage I disease at baseline; the histologic subtype  of  mesothelioma was epithelial in 68% of patients, mixed in 16%, sarcomatoid in 10% and other histologic subtypes  in 6%. The baseline demographics and tumor characteristics of the subgroup  of  fully  supplemented  patients  was  similar  to the overall study  population. 
  <br/>  The  efficacy  results from  Study  JMCH are summarized  in  
 
  <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark26">Table  18</linkHtml>and  
 
  <linkHtml href="file:///V:/Pharma/Products/Pemetrexed/Formulation/US/Somerset/Artwork/Working/PI/Final%20PI_RA/pemetrexed%20pi%2011%20Mar%2025-%2004%20Apr.docx#_bookmark26">Figure 9.</linkHtml>
                        </paragraph>
                        <paragraph/>
                        <table cellspacing="0" cellpadding="0" border="0" ID="t18" width="100%">
                           <caption>Table 18: Efficacy Results in Study JMCH</caption>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td rowspan="2" align="left" styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Efficacy Parameter</content>
                                    <br/>
                                 </td>
                                 <td colspan="2" align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">All Randomized and Treated Patients</content>
                                    <br/>
                                    <content styleCode="bold">(N=448)</content>
                                    <br/>
                                 </td>
                                 <td colspan="2" align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Fully Supplemented</content>
                                    <br/>
                                    <content styleCode="bold">Patients</content>
                                    <br/>
                                    <content styleCode="bold">(N=331)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Pemetrexed for injection /Cisplatin 
      <br/>  (N=226)
     </content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Cisplatin 
      <br/>  (N=222)
     </content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Pemetrexed for injection /Cisplatin 
      <br/>  (N=168)
     </content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Cisplatin 
      <br/>  (N=163)
     </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="top">Median overall survival (months) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">12.1 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">9.3 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">13.3 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">10.0 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="top">(95% CI) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">(10.0-14.4) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">(7.8-10.7) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">(11.4-14.9) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">(8.4-11.9) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="top">Hazard ratio
    
     <sup>a</sup>
                                    <br/>
                                 </td>
                                 <td colspan="2" align="center" styleCode="Rrule" valign="top">0.77 
     <br/>
                                 </td>
                                 <td colspan="2" align="center" styleCode="Rrule" valign="top">0.75 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule Rrule" valign="top">Log rank p-value 
     <br/>
                                 </td>
                                 <td colspan="2" align="center" styleCode="Rrule" valign="top">0.020 
     <br/>
                                 </td>
                                 <td colspan="2" align="center" styleCode="Rrule" valign="top">NA
    
     <sup>b</sup>
                                    <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>a Hazard ratios are not adjusted for stratification variables.</paragraph>
                        <paragraph>
                           <sup>b</sup>Not a pre-specified analysis.

 </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM12"/>
                           <br/>
                           <content styleCode="bold">
                              <br/>  Figure 9: Kaplan-Meier Curves for Overall Survival in Study JMCH 
   <br/>
                              <br/>
                           </content>
                        </paragraph>
                        <paragraph>
                           <br/>  Based upon prospectively defined criteria (modified Southwest Oncology Group methodology)  the  objective  tumor  response  rate  for  pemetrexed for injection  plus  cisplatin  was greater than the objective tumor response rate for cisplatin  alone.  There  was  also improvement in lung function (forced vital capacity) in the pemetrexed for injection plus cisplatin arm  compared to the control arm.
 </paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                     <component>
                        <observationMedia ID="MM12">
                           <text>Figure 9</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="figure-9.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s84">
               <id root="34c64c32-8a10-e0a0-e063-6394a90a8ddf"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES</title>
               <text>
                  <list listType="ordered" styleCode="Arabic">
                     <item>“OSHA Hazardous Drugs.”
  
   <content styleCode="italics">OSHA</content>.
  
   <content styleCode="italics">[https://www.osha.gov/hazardous-drugs]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250508"/>
            </section>
         </component>
         <component>
            <section ID="s85">
               <id root="34c64c32-8a11-e0a0-e063-6394a90a8ddf"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20250508"/>
               <component>
                  <section ID="s86">
                     <id root="34c64c32-8a12-e0a0-e063-6394a90a8ddf"/>
                     <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">How Supplied</content>
                        </paragraph>
                        <paragraph>Pemetrexed for injection USP, is a white-to-light yellow or green-yellow lyophilized powder supplied in single-dose vials for reconstitution for intravenous infusion.</paragraph>
                        <paragraph>NDC 70069-834-01: Carton containing one (1) single-dose vial of 100 mg pemetrexed.</paragraph>
                        <paragraph>NDC 70069-835-01: Carton containing one (1) single-dose vial of 500 mg pemetrexed.</paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
               <component>
                  <section ID="s87">
                     <id root="34c64c32-8a13-e0a0-e063-6394a90a8ddf"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Storage and Handling</content>
                        </paragraph>
                        <paragraph>Store at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F) [see USP Controlled Room Temperature]. </paragraph>
                        <paragraph>Pemetrexed for injection USP is a hazardous drug. Follow applicable special handling and disposal procedures. 
 
  <sup>﻿1</sup>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s88">
               <id root="34c64c32-8a14-e0a0-e063-6394a90a8ddf"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (
 
  <linkHtml href="#s98">Patient Information</linkHtml>).

 </paragraph>
               </text>
               <effectiveTime value="20250508"/>
               <component>
                  <section ID="s89">
                     <id root="34c64c32-8a15-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Premedication and Concomitant Medication</content>: Instruct patients to take folic acid as directed and to keep appointments for vitamin B
 
  <sub>12</sub>injections to reduce the risk of treatment-related toxicity. Instruct patients of the requirement to take corticosteroids to reduce the risks of treatment-related toxicity
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#s9">2.4</linkHtml>
                           </content>)
 
  <content styleCode="italics">and Warnings and Precautions (
  
   <linkHtml href="#s18">5.1</linkHtml>)
 
  </content>].

 </paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
               <component>
                  <section ID="s90">
                     <id root="34c64c32-8a16-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Myelosuppression</content>: Inform patients of the risk of low blood cell counts and instruct them to immediately contact their physician for signs of infection, fever, bleeding, or symptoms of anemia
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#s18">5.1</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
               <component>
                  <section ID="s91">
                     <id root="34c64c32-8a17-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Renal Failure</content>: Inform patients of the risks of renal failure, which may be exacerbated in patients with dehydration arising from severe vomiting or diarrhea. Instruct patients to immediately contact their healthcare provider for a decrease in urine output
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#s19">5.2</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
               <component>
                  <section ID="s92">
                     <id root="34c64c32-8a18-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Bullous and Exfoliative Skin Disorders</content>: Inform patients of the risks of severe and exfoliative skin disorders. Instruct patients to immediately contact their healthcare provider for development of bullous lesions or exfoliation in the skin or mucous membranes
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#s20">5.3</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
               <component>
                  <section ID="s93">
                     <id root="34c64c32-8a19-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Interstitial Pneumonitis</content>: Inform patients of the risks of pneumonitis. Instruct patients to immediately contact their healthcare provider for development of dyspnea or persistent cough
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#s21">5.4</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
               <component>
                  <section ID="s94">
                     <id root="34c64c32-8a1a-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Radiation Recall</content>: Inform patients who have received prior radiation of the risks of radiation recall. Instruct patients to immediately contact their healthcare provider for development of inflammation or blisters in an area that was previously irradiated
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#s22">5.5</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
               <component>
                  <section ID="s95">
                     <id root="34c64c32-8a1b-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Increased Risk of Toxicity with Ibuprofen in Patients with Renal Impairment</content>: Advise patients with mild to moderate renal impairment of the risks associated with concomitant ibuprofen use and instruct them to avoid use of all ibuprofen containing products for 2 days before, the day of, and 2 days following administration of pemetrexed for injection [
 
  <content styleCode="italics">see Dosage and Administration (2.5), Warnings and Precautions (5.6), and Drug Interactions (7)</content>].

 </paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
               <component>
                  <section ID="s96">
                     <id root="34c64c32-8a1c-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Embryo-Fetal Toxicity</content>: Advise females of reproductive potential and males with female partners of reproductive potential of the potential risk to a fetus
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#s24">5.7</linkHtml>) and Use in Specific Populations (
  
   <linkHtml href="#s37">8.1</linkHtml>)]
 
  </content>. Advise females of reproductive potential to use effective contraception during treatment with pemetrexed for injection and for 6 months after the last dose. Advise females to inform their prescriber of a known or suspected pregnancy. Advise males with female partners of reproductive potential to use effective contraception during treatment with pemetrexed for injection and for 3 months after the last dose
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#s24">5.7</linkHtml>) and Use in Specific Populations (
  
   <linkHtml href="#s43">8.3</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
               <component>
                  <section ID="s97">
                     <id root="34c64c32-8a1d-e0a0-e063-6394a90a8ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>: Advise women not to breastfeed during treatment with pemetrexed for injection and for 1 week after the last dose
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#s41">8.2</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <br/>
                              <br/>
                           </content>
                           <content styleCode="bold">
                              <br/>  Manufactured for:
  </content>
                           <br/>  Somerset Therapeutics, LLC. 
  <br/>  Somerset, NJ 08873 
  <br/>
                           <content styleCode="bold">Made  in   India</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s98">
               <id root="34c64c32-8a1e-e0a0-e063-6394a90a8ddf"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table cellspacing="0" cellpadding="0" border="0" width="100%">
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">PATIENT INFORMATION</content>
                              <br/>
                              <content styleCode="bold">Pemetrexed for injection </content>
                              <content styleCode="bold">(pem-e-TREX-ed for in-jec-tion)</content>
                              <br/>
                              <content styleCode="bold">for Intravenous Use</content>
                              <content styleCode="bold"/>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">What is Pemetrexed for injection?</content>
                              <br/>  Pemetrexed for injection is a prescription medicine used to treat: 
     <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">a kind of lung cancer called non-squamous non-small cell lung cancer (NSCLC).</content>
                                    <content styleCode="bold">Pemetrexed for injection is used</content>:
      
       <list listType="unordered" styleCode="Disc">
                                       <item>as the first treatment in combination with pembrolizumab and platinum chemotherapy when your lung cancer with no abnormal EGFR or ALK gene has spread (advanced NSCLC).</item>
                                       <item>as the first treatment in combination with cisplatin when your lung cancer has spread (advanced NSCLC).</item>
                                       <item>alone as maintenance treatment after you have received 4 cycles of chemotherapy that contains platinum for first treatment of your advanced NSCLC and your cancer has not progressed.</item>
                                       <item>alone when your lung cancer has returned or spread after prior chemotherapy.</item>
                                    </list>
                                 </item>
                              </list>
                              <br/>              Pemetrexed for injection is not for use for the treatment of people with squamous cell non-small cell lung cancer.  
     <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">a kind of cancer called malignant pleural mesothelioma.</content> This cancer affects the lining of the lungs and chest wall. Pemetrexed for injection is used in combination with cisplatin as the first treatment for malignant pleural mesothelioma that cannot be removed by surgery or you are not able to have surgery.
     
      </item>
                              </list>
                              <br/>  Pemetrexed for injection has not been shown to be safe and effective in children. 
   
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">Do not take pemetrexed for injection i</content>
                              <content styleCode="bold">f you have had a severe allergic reaction to any medicine that contains pemetrexed.</content>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">Before taking pemetrexed for injection, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have kidney problems.</item>
                                 <item>have had radiation therapy.</item>
                                 <item>are pregnant or plan to become pregnant. Pemetrexed for injection can harm your unborn baby.</item>
                              </list>
                              <br/>
                              <content styleCode="bold">                Females who are able to become pregnant:</content>
                              <br/>  Your healthcare provider will check to see if you are pregnant before you start treatment with pemetrexed for injection. You should use effective birth control (contraception) during treatment with pemetrexed for injection and for 6 months after the last dose. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with pemetrexed for injection. 
     <br/>
                              <content styleCode="bold">Males</content>with female partners who are able to become pregnant should use effective birth control (contraception) during treatment with pemetrexed for injection and for 3 months after the last dose.  
     <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>are breastfeeding or plan to breastfeed. It is not known if pemetrexed for injection passes into breast milk. Do not breastfeed during treatment with pemetrexed for injection and for 1 week after the last dose.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements. 
     <br/>
                              <content styleCode="bold">Tell your healthcare provider if you have kidney problems and take a medicine that contains ibuprofen</content>. You should avoid taking ibuprofen for 2 days before, the day of, and 2 days after receiving treatment with pemetrexed for injection. 
     <br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">How is pemetrexed for injection given?</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">It is very important to take folic acid and vitamin B
   
    <sub>12 </sub>during your treatment with pemetrexed for injection to lower your risk of harmful side effects.
  
   </content>
                        <list listType="unordered" styleCode="Disc">
                           <item>Take folic acid exactly as prescribed by your healthcare provider 1 time a day, beginning 7 days (1 week) before your first dose of pemetrexed for injection and continue taking folic acid until 21 days (3 weeks) after your last dose of pemetrexed for injection.</item>
                           <item>Your healthcare provider will give you vitamin B
    
     <sub>12</sub> injections during treatment with pemetrexed for injection. You will get your first vitamin B
    
     <sub>12</sub> injection 7 days (1 week) before your first dose of pemetrexed for injection, and then every 3 cycles.
   
    </item>
                           <item>Your healthcare provider will prescribe a medicine called corticosteroid for you to take 2 times a day for 3 days, beginning the day before each treatment with pemetrexed for injection.</item>
                           <item>Pemetrexed for injection is given to you by intravenous (IV) infusion into your vein. The infusion is given over 10 minutes.</item>
                           <item>Pemetrexed for injection is usually given 1 time every 21 days (3 weeks).</item>
                        </list>
                     </item>
                  </list>
                  <br/>
                  <table cellspacing="0" cellpadding="0" border="0" width="100%">
                     <tbody>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">What are the possible side effects of pemetrexed for injection?</content>
                              <br/>
                              <content styleCode="bold">Pemetrexed for injection can cause serious side effects, including:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Low blood cell counts.</content> Low blood cell counts can be severe, including low white blood cell counts (neutropenia), low platelet counts (thrombocytopenia), and low red blood cell counts (anemia). Your healthcare provider will do blood test to check your blood cell counts regularly during your treatment with pemetrexed for injection. 
      
       <content styleCode="bold">Tell your healthcare provider right away if you have any signs of infection, fever, bleeding, or severe tiredness during your treatment with pemetrexed for injection.</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Kidney problems, including kidney failure.</content> Pemetrexed for injection can cause severe kidney problems that can lead to death. Severe vomiting or diarrhea can lead to loss of fluids (dehydration) which may cause kidney problems to become worse. Tell your healthcare provider right away if you have a decrease in amount of urine.
     
      </item>
                                 <item>
                                    <content styleCode="bold">Severe skin reactions.</content> Severe skin reactions that may lead to death can happen with pemetrexed for injection. Tell your healthcare provider right away if you develop blisters, skin sores, skin peeling, or painful sores, or ulcers in your mouth, nose, throat or genital area.
     
      </item>
                                 <item>
                                    <content styleCode="bold">Lung problems (pneumonitis).</content> Pemetrexed for injection can cause serious lung problems that can lead to death. Tell your healthcare provider right away if you get any new or worsening symptoms of shortness of breath, cough, or fever.
     
      </item>
                                 <item>
                                    <content styleCode="bold">Radiation recall.</content> Radiation recall is a skin reaction that can happen in people who have received radiation treatment in the past and are treated with pemetrexed for injection. Tell your healthcare provider if you get swelling, blistering, or a rash that looks like a sunburn in an area that was previously treated with radiation.
     
      </item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">The most common side effects of pemetrexed for injection when given alone are:</content>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>tiredness</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode="Rrule" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>nausea</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>loss of appetite</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">The most common side effects of pemetrexed for injection when given with cisplatin are:</content>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" styleCode="Lrule Rrule" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>vomiting</item>
                                 <item>swelling or sores in your mouth or sore throat</item>
                                 <item>constipation</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode="Rrule" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>low white blood cell counts (neutropenia)</item>
                                 <item>low platelet counts (thrombocytopenia)</item>
                                 <item>low red blood cell counts (anemia)</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">The most common side effects of pemetrexed for injection when given with pembrolizumab and platinum chemotherapy are:</content>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" styleCode="Lrule Rrule" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>tiredness/weakness</item>
                                 <item>constipation</item>
                                 <item>loss of appetite</item>
                                 <item>vomiting</item>
                                 <item>shortness of breath</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode="Rrule" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>nausea</item>
                                 <item>diarrhea</item>
                                 <item>rash</item>
                                 <item>cough</item>
                                 <item>fever</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="justify" styleCode="Lrule Rrule" valign="top">Pemetrexed for injection may cause fertility problems in males. This may affect your ability to father a child. It is not known if these effects are reversible. Talk to your healthcare provider if this is a concern for you. 
     <br/>  Your healthcare provider will do blood test to check for side effects during treatment with pemetrexed for injection. Your healthcare provider may change your dose of pemetrexed for injection, delay treatment, or stop treatment if you have certain side effects. 
     <br/>  Tell your healthcare provider if you have any side effect that bothers you or that does not go away. 
     <br/>  These are not all the side effects of pemetrexed for injection. For more information, ask your healthcare provider or pharmacist. 
     <br/>  Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 
     <br/>
                              <br/>
                              <content styleCode="bold">General information about the safe and effective use of pemetrexed for injection.</content>
                              <br/>  Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. 
     <br/>  You can ask your pharmacist or healthcare provider for information about pemetrexed for injection that is written for health professionals. 
     <br/>
                              <br/>
                              <content styleCode="bold">What are the ingredients in pemetrexed for injection?</content>
                              <br/>
                              <content styleCode="bold">Active ingredient:</content> pemetrexed 
     <br/>
                              <content styleCode="bold">Inactive ingredients:</content> mannitol, hydrochloric acid and/or sodium hydroxide may have been added to adjust pH. 
     <br/>
                              <br/>
                              <br/>  Manufactured for: 
     <br/>  Somerset Therapeutics, LLC. 
     <br/>  Somerset, NJ 08873 
     <br/>  Made in India 
     <br/>
                              <br/>  This Patient Information has been approved by the U.S. Food and Drug Administration.        Revised: March 2025  
     <br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250508"/>
            </section>
         </component>
         <component>
            <section ID="s99">
               <id root="34c64c32-8a1f-e0a0-e063-6394a90a8ddf"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Label – Pemetrexed for Injection 100 mg single-dose vial</content>
                  </paragraph>
                  <paragraph>NDC 70069-834-01</paragraph>
                  <paragraph>Single-Dose Vial</paragraph>
                  <paragraph>Pemetrexed for Injection, USP</paragraph>
                  <paragraph>100 mg/vial</paragraph>
                  <paragraph>For intravenous use only.</paragraph>
                  <paragraph>Rx only 
  <br/>  Manufactured for:
 </paragraph>
                  <paragraph>Somerset Therapeutics LLC</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM13"/>
                  </paragraph>
                  <br/>
               </text>
               <effectiveTime value="20250508"/>
               <component>
                  <observationMedia ID="MM13">
                     <text>Label_Pemetrexed 100 mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="label-100-mg.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="La5411a14-a357-45f8-9297-76c566e2c545">
               <id root="34c64c32-8a20-e0a0-e063-6394a90a8ddf"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE CARTON – Pemetrexed for Injection 100 mg single-dose vial</content>
                  </paragraph>
                  <paragraph>NDC 70069-834-01</paragraph>
                  <paragraph>Single-Dose Vial</paragraph>
                  <paragraph>Pemetrexed for Injection, USP</paragraph>
                  <paragraph>100 mg/vial</paragraph>
                  <paragraph>For intravenous use only.</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>Manufactured for:</paragraph>
                  <paragraph>Somerset Therapeutics, LLC.</paragraph>
                  <paragraph>
                     <br/>  Pemetrexed100 mg_Carton 
  <br/>
                     <br/>
                     <renderMultiMedia referencedObject="MM14"/>
                     <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20250508"/>
               <component>
                  <observationMedia ID="MM14">
                     <text>Carton_Pemetrexed 100 mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="carton-100-mg.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s100">
               <id root="34c64c32-8a21-e0a0-e063-6394a90a8ddf"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Label Pemetrexed for Injection 500 mg single-dose vial</content>
                  </paragraph>
                  <paragraph>Single-Dose Vial</paragraph>
                  <paragraph>NDC 70069-835-01</paragraph>
                  <paragraph>Pemetrexed for Injection, USP</paragraph>
                  <paragraph>500 mg/vial</paragraph>
                  <paragraph>For intravenous use only.</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>Manufactured for:</paragraph>
                  <paragraph>Somerset Therapeutics, LLC.</paragraph>
                  <paragraph>
                     <br/>  Pemetrexed 500 mg_Label 
  <br/>
                     <br/>
                     <renderMultiMedia referencedObject="MM15"/>
                     <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20250508"/>
               <component>
                  <observationMedia ID="MM15">
                     <text>Label_Pemetrexed 500 mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="label-500-mg.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L18fab90f-d498-47f2-8214-4a6d29da93de">
               <id root="34c64c32-8a22-e0a0-e063-6394a90a8ddf"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE CARTON – Pemetrexed for Injection 500 mg single-dose vial</content>
                  </paragraph>
                  <paragraph>Single-Dose Vial</paragraph>
                  <paragraph>NDC 70069-835-01</paragraph>
                  <paragraph>Pemetrexed for Injection, USP</paragraph>
                  <paragraph>500 mg/vial</paragraph>
                  <paragraph>For intravenous use only.</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>Manufactured for:</paragraph>
                  <paragraph>Somerset Therapeutics, LLC.</paragraph>
                  <paragraph>
                     <br/>  Pemetrexed 500 mg_Carton 
  <br/>
                     <br/>
                     <renderMultiMedia referencedObject="MM16"/>
                     <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20250508"/>
               <component>
                  <observationMedia ID="MM16">
                     <text>Carton_Pemetrexed 500 mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="carton-500-mg.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>